[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 8061
1. Lü S, Yang J, Song X, Gong S, Zhou H, Guo L, Song N, Bao X, Chen P, Wang J: Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line. J Pharmacol Exp Ther; 2008 Aug;326(2):423-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
  • To study the mechanism of acquired resistance to bortezomib, a new antitumor drug that is the first therapeutic proteasome inhibitor, we established a series of bortezomib-resistant T lymphoblastic lymphoma/leukemia cell lines, designated the JurkatBs, from the parental Jurkat line via repeated drug selection.
  • The effects of bortezomib on cytotoxicity, cell cycle arrest, and induction of apoptosis were decreased in JurkatB cells compared with parental Jurkat cells.
  • [MeSH-minor] Bortezomib. Cell Cycle / drug effects. Cell Cycle / genetics. Cell Proliferation / drug effects. Cell Survival / drug effects. Cell Survival / genetics. Genetic Vectors. Humans. Jurkat Cells. Proteasome Inhibitors. Retroviridae / genetics. Tumor Stem Cell Assay

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502982.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / PSMB5 protein, human; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


2. Harila MJ, Salo J, Lanning M, Vilkkumaa I, Harila-Saari AH: High health-related quality of life among long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer; 2010 Aug;55(2):331-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High health-related quality of life among long-term survivors of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Health-related quality of life (HRQoL) was assessed in a cohort of long-term childhood acute lymphoblastic leukemia (ALL) survivors.
  • PROCEDURE: Rand-36-Item health Survey (RAND-36) was used to assess subjective HRQoL in 74 survivors of ALL an average of 20 years after the diagnosis.
  • Survivors were examined by a physician and late effects were graded using the Common Terminology Criteria for Adverse Events (CTCAEv3).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Quality of Life. Survivors / psychology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582965.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Whyte M, Irving H, O'Regan P, Nissen M, Siebert D, Labrom R: Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia. Pediatr Infect Dis J; 2005 Apr;24(4):375-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated Scedosporium prolificans infection and survival of a child with acute lymphoblastic leukemia.
  • We report on a pediatric patient who developed overwhelming S. prolificans sepsis after induction chemotherapy for acute lymphoblastic leukemia.
  • She is well 18 months after the diagnosis of fungal sepsis and continues to receive chemotherapy for leukemia, which remains in remission.
  • [MeSH-major] Fungemia / drug therapy. Fungemia / microbiology. Mycetoma / drug therapy. Mycetoma / microbiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Scedosporium / isolation & purification

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15818301.001).
  • [ISSN] 0891-3668
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Naphthalenes; 0 / Pyrimidines; 0 / Triazoles; G7RIW8S0XP / terbinafine; JFU09I87TR / Voriconazole
  •  go-up   go-down


Advertisement
4. Baptista MJ, Rocha G, Clemente F, Azevedo LF, Tibboel D, Leite-Moreira AF, Guimarães H, Areias JC, Correia-Pinto J: N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants. Neonatology; 2008;94(1):22-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] N-terminal-pro-B type natriuretic peptide as a useful tool to evaluate pulmonary hypertension and cardiac function in CDH infants.
  • Plasmatic N-terminal-pro-B type natriuretic peptide (NT-proBNP) might be useful in diagnosis and management of PH in newborns, although its interest in CDH infants remains to be defined.
  • [MeSH-major] Heart / physiopathology. Hernia, Diaphragmatic / physiopathology. Hernias, Diaphragmatic, Congenital. Hypertension, Pulmonary / blood. Hypertension, Pulmonary / diagnosis. Natriuretic Peptide, Brain / blood. Peptide Fragments / blood

  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 S. Karger AG, Basel.
  • (PMID = 18160811.001).
  • [ISSN] 1661-7819
  • [Journal-full-title] Neonatology
  • [ISO-abbreviation] Neonatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


5. Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, Collinson PO, McKenna WJ, Elliott PM: Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. Am J Cardiol; 2006 Aug 15;98(4):515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy.
  • The aim of this study was to determine the usefulness of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) as a marker of exercise performance in HC.
  • Plasma NT-pro-BNP was measured in 171 consecutive patients (mean age 46 +/- 18 years) who underwent echocardiography and cardiopulmonary exercise testing.
  • The mean log NT-pro-BNP was 2.79 +/- 0.5; log NT-pro-BNP levels were higher in women patients (p = 0.001) and patients with chest pain (p = 0.010), in New York Heart Association class > or = II (p = 0.009), with atrial fibrillation (p < 0.001), with systolic impairment (p = 0.025), and with LV outflow tract obstructions (p < 0.0001).
  • NT-pro-BNP levels were also correlated with maximal wall thickness (r = 0.335, p < 0.0001), left atrial size (r = 0.206, p = 0.007), and the mitral Doppler E/A ratio (r = 0.197, p = 0.012).
  • There were inverse correlations between percent VO2max and NT-pro-BNP (r = -0.352, p = 0.001), LV end-systolic cavity size (r = -0.182, p = 0.031), and left atrial size (r = -0.251, p = 0.003).
  • On multivariate analysis, only NT-pro-BNP was correlated with percent VO2max.
  • A NT-pro-BNP level of 316 ng/L had 78% sensitivity and 44% specificity (area under the curve 0.616) for predicting percent VO2max < 80%.
  • In conclusion, NT-pro-BNP levels correlate with peak oxygen consumption in HC and are more predictive of functional impairment than other conventional markers of disease severity.

  • Genetic Alliance. consumer health - Cardiomyopathy.
  • Genetic Alliance. consumer health - Hypertrophic Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16893708.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


6. Abd El-Ghaffar HA, Aladle DA, Farahat SE, Abd El-Hady N: P-glycoprotein (P-170) expression in acute leukemias. Hematology; 2006 Feb;11(1):35-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P-glycoprotein (P-170) expression in acute leukemias.
  • Multidrug resistance (MDR) is still a major obstacle to chemotherapy success in acute myeloid leukemia (AML) and to a less extent acute lymphoblastic leukemia (ALL).
  • This study was planned to study the expression of P-glycoprotein/170 in patients with acute leukemia and the effect of Cyclosporin A (CSA) as a modulator of P-glycoprotein functional activity.
  • The study was carried out on 20 patients with acute leukemia (14 AML cases and 6 ALL cases).
  • Flow cytometric analysis of P-gp/170 surface expression was performed using UIC-2 MoAb together with the functional assay using Rhodamine 123 (Rh 123) and Cyclosporin A as a modulator.P-gp/170 was expressed on the leukemic cells of 37.5% of relapsed patients (40.0% of AML and 33.3% of ALL cases), whereas 27.2% of de novo patients expressed P-gp/170 (33.3% of AML cases and 0% of ALL cases).
  • From this study, it is clear that P-gp/170 is expressed to a higher degree in leukemic cells and this is greater in relapsed compared to de novo cases and more in AML than ALL blasts.
  • [MeSH-major] Drug Resistance, Multiple. Drug Resistance, Neoplasm. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / metabolism. P-Glycoprotein / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16522547.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / P-Glycoprotein
  •  go-up   go-down


7. Alonso CN, Meyer C, Gallego MS, Rossi JG, Mansini AP, Rubio PL, Medina A, Marschalek R, Felice MS: BTBD18: A novel MLL partner gene in an infant with acute lymphoblastic leukemia and inv(11)(q13;q23). Leuk Res; 2010 Nov;34(11):e294-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BTBD18: A novel MLL partner gene in an infant with acute lymphoblastic leukemia and inv(11)(q13;q23).
  • [MeSH-major] Chromosome Inversion. Myeloid-Lymphoid Leukemia Protein / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598370.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  •  go-up   go-down


8. Infante-Rivard C, Siemiatycki J, Lakhani R, Nadon L: Maternal exposure to occupational solvents and childhood leukemia. Environ Health Perspect; 2005 Jun;113(6):787-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maternal exposure to occupational solvents and childhood leukemia.
  • We carried out a population-based case-control study including 790 incident cases of childhood acute lymphoblastic leukemia and as many healthy controls, matched on age and sex.
  • Maternal occupational exposure to solvents before and during pregnancy was estimated using the expert method, which involves chemists coding each individual's job for specific contaminants.
  • The frequency of exposure to specific agents or mixtures was generally low.
  • Increased risks were observed for specific exposures, such as to 1,1,1-trichloroethane (OR = 7.55; 95% CI, 0.92-61.97), toluene (OR = 1.88; 95% CI, 1.01-3.47), and mineral spirits (OR = 1.82; 95% CI, 1.05-3.14).
  • Using an elaborate exposure coding method, this study shows that maternal exposure to solvents in the workplace does not seem to play a major role in childhood leukemia.
  • [MeSH-major] Maternal Exposure. Occupational Exposure. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Solvents / toxicity

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • MedlinePlus Health Information. consumer health - Reproductive Hazards.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Am J Ind Med. 2003 May;43(5):519-22 [12704624.001]
  • [Cites] Tumori. 1990 Oct 31;76(5):413-9 [2256184.001]
  • [Cites] Eur J Cancer. 1991;27(8):958-65 [1832903.001]
  • [Cites] Cancer Causes Control. 1992 Mar;3(2):161-9 [1562706.001]
  • [Cites] Am J Epidemiol. 1996 Feb 15;143(4):363-73 [8633620.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):406-19 [9498902.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:909-25 [9646055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):783-91 [10498397.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):835-8 [10952101.001]
  • [Cites] Am J Ind Med. 2000 Dec;38(6):609-18 [11071683.001]
  • [Cites] Br J Cancer. 2000 Dec;83(11):1559-64 [11076669.001]
  • [Cites] Epidemiology. 2003 Jul;14(4):437-41 [12843769.001]
  • [Cites] Occup Environ Med. 2003 Dec;60(12):901-9 [14634180.001]
  • [Cites] J Epidemiol Community Health. 1981 Mar;35(1):11-5 [7264527.001]
  • [Cites] J Occup Med. 1982 Aug;24(8):578-84 [6750059.001]
  • [Cites] IARC Monogr Eval Carcinog Risk Chem Hum. 1983 Dec;32:1-453 [6586639.001]
  • [Cites] Am J Epidemiol. 1985 Feb;121(2):216-24 [3860001.001]
  • [Cites] J Occup Med. 1985 Jun;27(6):420-6 [4020500.001]
  • [Cites] Arch Dis Child. 1987 Mar;62(3):279-87 [3646026.001]
  • [Cites] J Natl Cancer Inst. 1987 Jul;79(1):39-46 [3474448.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1378-84 [3621121.001]
  • [Cites] Scand J Work Environ Health. 1987 Dec;13(6):486-92 [3433050.001]
  • [Cites] Epidemiology. 2001 Jan;12(1):13-9 [11138808.001]
  • [Cites] Am J Public Health. 2001 Apr;91(4):564-7 [11291366.001]
  • [Cites] Am J Ind Med. 2001 Jun;39(6):531-46 [11385637.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Occup Environ Med. 2002 Sep;59(9):575-93; discussion 594 [12205230.001]
  • [Cites] Am J Epidemiol. 2003 Jan 15;157(2):176-82 [12522025.001]
  • [Cites] Cancer. 1988 Aug 1;62(3):635-44 [3164642.001]
  • (PMID = 15929905.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkanes; 0 / Hydrocarbons, Aromatic; 0 / Solvents
  • [Other-IDs] NLM/ PMC1257608
  •  go-up   go-down


9. Kaya Z, Gursel T, Bakkaloglu SA, Kocak U, Atasever T, Oktar SO: Evaluation of renal function in Turkish children receiving BFM-95 therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2007 Jun;24(4):257-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of renal function in Turkish children receiving BFM-95 therapy for acute lymphoblastic leukemia.
  • This study examined renal function in 42 children with acute lymphoblastic leukemia (ALL) treated according to BFM-95 protocol.
  • There was only mild tubular abnormality in 5.8% of patients (n = 17) in group 3, who were examined at a single time point a mean of 56.1 +/- 12.5 months after completion chemotherapy.
  • These data show that consolidation therapy with HDMTX is frequently associated with acute renal toxicity in children with ALL but does not leave clinically significant late sequelae.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Diseases / chemically induced. Methotrexate / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613868.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; ALL-BFM-95 protocol
  •  go-up   go-down


10. Doerfel C, Rump A, Sauerbrey A, Gruhn B, Zintl F, Steinbach D: In acute leukemia, the polymorphism -211C&gt;T in the promoter region of the multidrug resistance-associated protein 3 (MRP3) does not determine the expression level of the gene. Pharmacogenet Genomics; 2006 Feb;16(2):149-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In acute leukemia, the polymorphism -211C>T in the promoter region of the multidrug resistance-associated protein 3 (MRP3) does not determine the expression level of the gene.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Myeloid, Acute / genetics. Multidrug Resistance-Associated Proteins / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827851319 for PMID:16424827 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424827.001).
  • [ISSN] 1744-6872
  • [Journal-full-title] Pharmacogenetics and genomics
  • [ISO-abbreviation] Pharmacogenet. Genomics
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / multidrug resistance-associated protein 3
  •  go-up   go-down


11. Barry E, DeAngelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB: Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol; 2007 Mar 1;25(7):813-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.
  • PURPOSE: Historically, adolescents with acute lymphoblastic leukemia (ALL) have had inferior outcomes when compared with younger children.
  • Adolescents were more likely to present with T-cell phenotype (P < .001) and less likely to have the TEL-AML1 fusion (P = .05).
  • CONCLUSION: Adolescents were more likely to present at diagnosis with biologically higher risk disease (T-cell phenotype and absence of the TEL-AML1 fusion) and more likely to experience treatment-related complications than younger children.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17327603.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 68484
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Oncogene Proteins, Fusion; 0 / TEL-AML1 fusion protein; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


12. Liu Y, Tang JY, Xu C, Gu LJ, Xue HL, Chen J, Pan C, Dong L, Zhou M: [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia]. Zhonghua Er Ke Za Zhi; 2009 May;47(5):366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of effective antigen combinations in childhood B lineage acute lymphoblastic leukemia].
  • OBJECTIVE: To probe into the occurrence rates of the effective antigen combinations which were used to detect the minimal residual disease (MRD) by flow cytometry in childhood B-lineage acute lymphoblastic leukemia (B-ALL), as well as the relationship between clinical-biologic factors and different combinations.
  • [MeSH-major] Leukemia, B-Cell / immunology. Leukemia, B-Cell / therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy


13. Monma F, Nishii K, Ezuki S, Miyazaki T, Yamamori S, Usui E, Sugimoto Y, Lorenzo V F, Katayama N, Shiku H: Molecular and phenotypic analysis of Philadelphia chromosome-positive bilineage leukemia: possibility of a lineage switch from T-lymphoid leukemic progenitor to myeloid cells. Cancer Genet Cytogenet; 2006 Jan 15;164(2):118-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and phenotypic analysis of Philadelphia chromosome-positive bilineage leukemia: possibility of a lineage switch from T-lymphoid leukemic progenitor to myeloid cells.
  • The occurrence of acute bilineage leukemia is thought to be the malignant transformation of a myeloid or lymphoid leukemic progenitor with the potential to differentiate into the other lineages; however, the mechanisms of this lineage switch are not well understood.
  • Here, we report on the extremely rare case of adult Philadelphia chromosome-positive acute bilineage leukemia, which is characterized by T-cell acute lymphoblastic leukemia and acute myelomonocytic leukemia.
  • When the CD5+ and CD5- cells were sorted, a fusion gene of BCR/ABL and the same clonally rearranged band of a T-cell receptor (TCR) gene were detected in both populations.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / pathology. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology. Philadelphia Chromosome
  • [MeSH-minor] Cell Lineage. Fusion Proteins, bcr-abl / genetics. Gene Rearrangement. Humans. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Lymphocyte Subsets. Male. Middle Aged. Myeloid Progenitor Cells / pathology. Receptors, Antigen, T-Cell, gamma-delta / genetics. Translocation, Genetic. Treatment Failure

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434313.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell, gamma-delta; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


14. Yan HM, Ji SQ, Chen HR, Duan LN, Zhu L, Liu J, Xue M, Ding L, Wang HX: [Clinical investigation on treatment of children leukemia with non-T-cell depleted haploidentical bone marrow transplantation]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb;16(1):101-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical investigation on treatment of children leukemia with non-T-cell depleted haploidentical bone marrow transplantation].
  • To investigate the efficacy and feasibility of parent non-T cell depleted haploidentical bone marrow transplants (haploidentical BMT) for children with leukemia, the efficacy of haploidentical BMT was evaluated in 8 leukemia children (1.9-9 years) received hematopoietic stem cell transplantation, donors were their parents with HLA-mismatched for two or three loci.
  • Five children were pre-conditioned with a myeloablative regimen consisting of high-dose cytarabine (Ara-C), cyclophosphamide (CY) and total body irradiation.
  • The donors were given G-CSF prior to marrow harvest and the non-T-cell depleted grafts were used.
  • Incidence of lethal aGVHD was lower, II-III acute aGVHD was found only in one out of eight patients.
  • During the follow-up of 33 months (range 7-56 months), two patients died from relapsed leukemia, including one relapsed as donor-origin leukemia.
  • It is concluded that above-mentioned preconditioning regimen and GVHD prophylaxis procedure in non-T-cell depleted bone marrow transplantation from HLA-mismatched parents are effective approaches and safe strategy for the treatment of children leukemia.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315910.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Tsai AG, Yoda A, Weinstock DM, Lieber MR: t(X;14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not. Blood; 2010 Sep 16;116(11):1993-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] t(X;14)(p22;q32)/t(Y;14)(p11;q32) CRLF2-IGH translocations from human B-lineage ALLs involve CpG-type breaks at CRLF2, but CRLF2/P2RY8 intrachromosomal deletions do not.
  • [MeSH-major] Chromosome Breakage. Immunoglobulin Heavy Chains / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptors, Cytokine / genetics. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847213.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA100504; United States / NCI NIH HHS / CA / R01 CA151898; United States / NCI NIH HHS / CA / R37 CA051105
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRLF2 protein, human; 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Cytokine; 0 / Receptors, Purinergic P2
  •  go-up   go-down


16. Izraeli S: Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside? Br J Haematol; 2010 Oct;151(2):119-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of genomics for risk stratification of childhood acute lymphoblastic leukaemia: from bench to bedside?
  • The remarkable progress in the treatment of childhood acute lymphoblastic leukaemia (ALL) has been based on the adjustment of therapy to subgroups of leukaemia stratified by their prognostic implications.
  • The application of genomics for routine diagnosis of ALL is feasible but depends on commercial development of appropriate certified platforms.
  • [MeSH-major] Genomics / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20678159.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  •  go-up   go-down


17. Zimmermann A, Weinand F, Lorenz B: [Unilateral loss of visual function with edema of the optic nerve in a 35-year-old male patient]. Ophthalmologe; 2010 Nov;107(11):1072-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ocular manifestations of acute lymphoblastic leukemia (ALL) are manifold.
  • [MeSH-major] Blindness / etiology. Leukemic Infiltration / diagnosis. Orbit / pathology. Papilledema / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Retina / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Fundus Oculi. Humans. Magnetic Resonance Imaging. Male. Retinal Detachment / diagnosis. Retinal Hemorrhage / diagnosis. Retinoscopy. Tomography, Optical Coherence

  • Genetic Alliance. consumer health - Edema.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 1988 Mar 15;105(3):294-8 [3422790.001]
  • [Cites] Retina. 2006 Jul-Aug;26(6):710-2 [16829822.001]
  • [Cites] Br J Ophthalmol. 2000 Nov;84(11):1318-9 [11203168.001]
  • [Cites] Am J Ophthalmol. 2003 Jan;135(1):94-6 [12504706.001]
  • [Cites] Acta Ophthalmol Scand. 2004 Feb;82(1):81-5 [14738490.001]
  • [Cites] Retina. 1989;9(2):110-4 [2772418.001]
  • [Cites] Arch Soc Esp Oftalmol. 2007 Mar;82(3):167-70 [17357894.001]
  • [Cites] J Pediatr. 2006 May;148(5):703 [16737892.001]
  • [Cites] Eye (Lond). 2004 Jul;18(7):663-72 [15002029.001]
  • (PMID = 20535476.001).
  • [ISSN] 1433-0423
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Athanassiadou F, Tragiannidis A, Rousso I, Katsos G, Sidi V, Papageorgiou T, Papastergiou C, Tsituridis I, Koliouskas D: Bone mineral density in survivors of childhood acute lymphoblastic leukemia. Turk J Pediatr; 2006 Apr-Jun;48(2):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone mineral density in survivors of childhood acute lymphoblastic leukemia.
  • The aim of our study was to evaluate bone metabolism with measurement of bone mineral density (BMD) after management (chemo-, radiotherapy) for childhood acute lymphoblastic leukemia (ALL).
  • Bone mineral density (g/cm2) of lumbar spine was measured by dual energy X-ray absorptiometry (Norland bone densitometer) in 18 children with ALL and a median of 34 months' post-diagnosis with no history of relapse, secondary malignancy, or transplantation.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bone Diseases, Metabolic / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications


19. Rodig SJ, Shahsafaei A, Li B, Mackay CR, Dorfman DM: BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol; 2005 Oct;36(10):1113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders.
  • B cell-activating factor receptor (BAFF-R) is one of three known receptors for BAFF, a critical regulator of B- and T-cell function.
  • In mice, BAFF-R is required for B-cell maturation and survival, and in mice and humans, the overproduction of BAFF is associated with autoimmune disease.
  • We sought to determine the normal pattern of BAFF-R expression at specific stages of B- and T-cell development and whether this pattern of expression corresponds with related B- and T-cell neoplasms.
  • In reactive lymphoid tissues, BAFF-R is expressed by B cells colonizing the mantle zones, by a subset of cells within germinal centers, and rare cells in the interfollicular T-cell zone.
  • Seventy-seven (78%) of 116 cases of B-cell lymphoproliferative disorders were BAFF-R-positive by immunohistochemical and/or flow cytometric immunophenotypic analysis, including most cases of mantle cell lymphoma, follicular lymphoma, marginal zone lymphoma, chronic lymphocytic leukemia, hairy cell leukemia, and diffuse large B-cell lymphoma.
  • In contrast, cases of precursor B lymphoblastic lymphoma, Burkitt lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma exhibit weak to negative staining for BAFF-R.
  • All cases of classical Hodgkin lymphoma and T-cell lymphomas were BAFF-R-negative, including all cases of anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma, unspecified.
  • These findings highlight BAFF-R as a marker of both normal and neoplastic B cells and raise the possibility that BAFF-R expression is necessary for the survival of a subset of neoplastic B lymphocytes analogous to its known role in promoting normal B-cell maturation and survival.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226112.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Interleukin-4
  •  go-up   go-down


20. Whitehead VM, Shuster JJ, Vuchich MJ, Mahoney DH Jr, Lauer SJ, Payment C, Koch PA, Cooley LD, Look AT, Pullen DJ, Camitta B: Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia; 2005 Apr;19(4):533-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
  • We reported that children with B-progenitor-cell acute lymphoblastic leukemia (BpALL) treated in the early 1980s whose lymphoblasts accumulated high levels of methotrexate (MTX) and of methotrexate polyglutamates (MTXPGs) in vitro had an improved 5-year event-free survival (EFS) (65% (standard error (s.e.
  • [MeSH-major] Antimetabolites, Antineoplastic / pharmacokinetics. Methotrexate / analogs & derivatives. Methotrexate / pharmacokinetics. Polyglutamic Acid / analogs & derivatives. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15716987.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-03161; United States / NCI NIH HHS / CA / CA-15989; United States / NCI NIH HHS / CA / CA-25408; United States / NCI NIH HHS / CA / CA-28841; United States / NCI NIH HHS / CA / CA-29139; United States / NCI NIH HHS / CA / CA-29691; United States / NCI NIH HHS / CA / CA-31566; United States / NCI NIH HHS / CA / CA-32053; United States / NCI NIH HHS / CA / CA-33587; United States / NCI NIH HHS / CA / CA-33625; United States / NCI NIH HHS / CA / CA-52317; United States / NCI NIH HHS / CA / CA-53490
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 25513-46-6 / Polyglutamic Acid; 82334-40-5 / methotrexate polyglutamate; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


21. Imamura T, Morimoto A, Kato R, Izumi M, Murakami A, Matuo S, Kiyosawa N, Kano G, Yoshioka H, Sugimoto T, Imashuku S: Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase-containing chemotherapy. Leuk Lymphoma; 2005 May;46(5):729-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase-containing chemotherapy.
  • For determining risk factors, we retrospectively analysed hemostatic markers in 19 pediatric patients with leukemia or lymphoma who were treated with either 1 of the 2 L-asparaginase-containing regimens; 11 were treated with VLP1 and the remaining 8 were treated with the VLAD protocol.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Asparaginase / adverse effects. Intracranial Thrombosis / chemically induced. Lymphoma, Non-Hodgkin / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019511.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fibrin Fibrinogen Degradation Products; 0 / fibrin fragment D; 9000-94-6 / Antithrombin III; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


22. Suggs JL, Cruse JM, Lewis RE: Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias. Exp Mol Pathol; 2007 Dec;83(3):471-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant myeloid marker expression in precursor B-cell and T-cell leukemias.
  • The World Health Organization (WHO) characterization of the immunophenotype of precursor B-cell acute lymphoblastic leukemia (pre-B ALL) includes the possible expression of myeloid cluster of differentiation (CD) markers CD13 and CD33.
  • In precursor T-cell acute lymphoblastic leukemia (pre-T ALL), myeloid markers CD13 and CD33 are frequent while CD117 is rare.
  • In the present investigation, 71 cases of confirmed pre-B ALL were evaluated for the presence of CD13 and CD33.
  • Twenty-one cases of confirmed pre-T ALL were analyzed for myeloid markers CD13, CD33, CD117, and MPO.
  • [MeSH-major] Biomarkers / metabolism. Leukemia, B-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. Precursor Cells, B-Lymphoid / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17963747.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers
  •  go-up   go-down


23. Teitell MA, Pandolfi PP: Molecular genetics of acute lymphoblastic leukemia. Annu Rev Pathol; 2009;4:175-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetics of acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) is mainly a disease of childhood that arises from recurrent genetic insults that block precursor B and T cell differentiation and drive aberrant cell proliferation and survival.
  • Recurrent defects including chromosomal translocations, aneuploidies, and gene-specific alterations generate molecular subgroups of B- and T-ALL with differing clinical courses and distinct responses to therapy.
  • Recent discoveries arising from genome-wide surveys and adoptive transfer of leukemia-initiating cells have uncovered multiple gene copy number aberrations and have yielded new insight into at least one type of ALL-originating cell.
  • Our understanding of the pathogenesis of ALL has benefited from genetically modified mouse models that recapitulate cellular transformation at specific developmental stages of lymphoid lineage cells.
  • Here, we review the spectrum of genetic aberrations that promote acute B and T cell leukemias and the mechanisms of cell transformation and malignant progression that are reinforced by mouse models of human ALL.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Gene Expression Regulation, Leukemic. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Animals. Cell Differentiation / genetics. Cell Lineage / genetics. Cell Proliferation. Disease Models, Animal. Genotype. Humans. Mice. Phenotype. Signal Transduction / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783329.001).
  • [ISSN] 1553-4014
  • [Journal-full-title] Annual review of pathology
  • [ISO-abbreviation] Annu Rev Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 153
  •  go-up   go-down


24. Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O'Brien S, Keating M, Albitar M: Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res; 2007 Jun;31(6):791-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
  • We investigated whether abnormal phosphorylation of FLT3 may be more common in AML.
  • We evaluated FLT3 protein and its phosphorylation in the plasma from 85 patients with AML, 16 patients with myelodysplastic syndrome (MDS) and 5 patients with acute lymphoblastic leukemia (ALL).
  • [MeSH-major] Leukemia, Myeloid, Acute / blood. Protein Processing, Post-Translational. fms-Like Tyrosine Kinase 3 / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Differentiation / genetics. Cell Proliferation. Female. Hematopoietic Stem Cells. Humans. Male. Membrane Proteins / genetics. Middle Aged. Myelodysplastic Syndromes / blood. Myelodysplastic Syndromes / genetics. Myelodysplastic Syndromes / mortality. Myelodysplastic Syndromes / therapy. Phosphorylation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Remission Induction


25. Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, Jakubas B, Palynyczko G, Lewandowski K, Dmoszynska A, Skotnicki A, Nowak K, Holowiecki J, Polish Adult Leukemia Group: Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG). Ann Hematol; 2006 Oct;85(10):717-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
  • Outcome of adults with acute lymphoblastic leukemia (ALL) who fail to achieve complete remission (CR) or who relapse soon after initial response is poor.
  • The goal of this phase II study by the Polish Adult Leukemia Group (PALG) was to evaluate safety and efficacy of a new salvage regimen (FLAM) consisting of sequential fludarabine, cytarabine, and mitoxantrone.
  • Fifty patients were included with primary (n = 13) or secondary (n = 5) refractoriness, early (<12 months) first relapse (n = 15), first relapse after hematopoietic cell transplantation (HCT) regardless CR duration (n = 13), and second or subsequent relapse (n = 4).
  • CR rate equaled 50% and was significantly higher for patients in whom FLAM was administered as a second-line therapy compared to those more heavily pre-treated (66 vs 13%, p = 0.02).
  • Seventeen patients had leukemia regrowth after initial cytoreduction, whereas, eight patients died in aplasia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Cytarabine / administration & dosage. Cytarabine / adverse effects. Disease-Free Survival. Female. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Mitoxantrone / adverse effects. Poland. Recurrence. Remission Induction. Sepsis / etiology. Time Factors. Transplantation, Homologous. Vidarabine / administration & dosage. Vidarabine / adverse effects. Vidarabine / analogs & derivatives

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832677.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; FLAM regimen
  •  go-up   go-down


26. Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD: Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. Pediatr Blood Cancer; 2006 Feb;46(2):179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
  • PURPOSE: A previous Pediatric Oncology Group (POG) study showed high incidence of secondary acute myelogenous leukemia (AML) in children treated for T-cell acute lymphoblastic leukemia (T-ALL) or higher-stage lymphoblastic lymphoma.
  • The most common toxicities were Grade 3 or 4 myelosuppression after cyclophosphamide/cytarabine and allergic reactions to asparaginase.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007607.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U10 CA5312; United States / NCI NIH HHS / CA / CA29139
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


27. Swierczynski SL, Hafez MJ, Philips J, Higman MA, Berg KD, Murphy KM: Bone marrow engraftment analysis after granulocyte transfusion. J Mol Diagn; 2005 Aug;7(3):422-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a 6-year-old male who received an allogeneic bone marrow transplant as part of treatment for acute lymphoblastic leukemia.
  • This case illustrates that white cell transfusion can lead to erroneous bone marrow engraftment results, particularly if only one microsatellite locus is used to monitor engraftment.
  • [MeSH-major] Bone Marrow Transplantation. DNA / analysis. Graft Survival / genetics. Leukocyte Transfusion. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2000 Jan;113(1):135-40 [10631867.001]
  • [Cites] Clin Lab Med. 2000 Mar;20(1):197-225 [10702903.001]
  • [Cites] Leukemia. 2001 Feb;15(2):293-302 [11236950.001]
  • [Cites] Bone Marrow Transplant. 2002 Feb;29(3):243-8 [11859397.001]
  • [Cites] Mol Diagn. 1999 Jun;4(2):153-7 [10462630.001]
  • [Cites] Leukemia. 2004 Feb;18(2):248-54 [14671648.001]
  • [Cites] Acta Haematol. 2004;112(1-2):16-23 [15179000.001]
  • [Cites] Bone Marrow Transplant. 1999 May;23(10):1055-60 [10373073.001]
  • [Cites] J Mol Diagn. 2002 Nov;4(4):230-2 [12411591.001]
  • (PMID = 16049315.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC1867546
  •  go-up   go-down


28. Clark BR, Ferketich AK, Fisher JL, Ruymann FB, Harris RE, Wilkins JR 3rd: Evidence of population mixing based on the geographical distribution of childhood leukemia in Ohio. Pediatr Blood Cancer; 2007 Nov;49(6):797-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of population mixing based on the geographical distribution of childhood leukemia in Ohio.
  • BACKGROUND: This ecologic study examined the geographic distribution of childhood leukemias in Ohio, 1996-2000, among children aged 0-19 for evidence that population mixing may be a factor.
  • SEER*Stat version 5.0 was used to derive age-specific and 0-19 age-adjusted rates.
  • RESULTS: Of the 585 cases, 73.3% were acute lymphocytic leukemia (ALL), 16.6% acute myelogenous leukemia (AML), 3.2% acute monocytic leukemia (AMoL), and 2.6% chronic myelogenous leukemia (CML).
  • Rates for total leukemia burden were significantly below national levels for all races (P = 0.00001), likely due to poor ascertainment of cases.
  • [MeSH-major] Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Population Density. Population Dynamics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Rural Population. Urban Population


29. Matteucci C, Barba G, Varasano E, Vitale A, Mancini M, Testoni N, Cuneo A, Rege-Cambrin G, Elia L, La Starza R, Pierini V, Brandimarte L, Vignetti M, Foà R, Mecucci C, GIMEMA Acute Leukaemia Working Party, Italy: Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study. Br J Haematol; 2010 Apr;149(1):70-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rescue of genomic information in adult acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics: a GIMEMA centralized biological study.
  • Metaphase (M-) and array (A-) Comparative Genomic Hybridization (CGH) were used to investigate 40 cases of T- and 32 of B-cell acute lymphoblastic leukaemia (ALL) with normal/failed cytogenetics.
  • We suggest that the work-up for ALL at diagnosis should include CGH investigations, particularly when cytogenetics is uninformative, because they may provide potentially valuable information with prognostic and therapeutic implications.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20067559.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


30. Gleissner B, Goekbuget N, Rieder H, Arnold R, Schwartz S, Diedrich H, Schoch C, Heinze B, Fonatsch C, Bartram CR, Hoelzer D, Thiel E, GMALL Study Group: CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood; 2005 Dec 15;106(13):4054-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL).
  • Immunophenotyping disclosed CD10 negativity in 70 of 2408 cases of B-lineage acute lymphoblastic leukemia (ALL), although other criteria followed classification of pre-B ALL (eg, cytoplasmic immunoglobulin positivity).
  • Although 83% of the patients achieved complete remission, the remission duration remained remarkably low: 141 days for MLL rearrangement-positive and 245 days for MLL rearrangement-negative CD10(-) pre-B ALL.
  • Thus, the overall survival probability 3 years after diagnosis was 0.34 +/- 0.20 SE in MLL-rearrangement-negative versus 0.12 +/- 0.06 SE in MLL rearrangement-positive CD10- pre-B ALL.
  • Our data identify CD10- cytoplasmic immunoglobulin-positive pre-B ALL as a rare (2.2%) but distinct immuno-subtype of adult ALL that is characterized by a high MLL rearrangement rate and a worse outcome.
  • [MeSH-major] Chromosome Aberrations. Neprilysin / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123216.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


31. Fullmer A, O'Brien S, Kantarjian H, Jabbour E: Emerging therapy for the treatment of acute lymphoblastic leukemia. Expert Opin Emerg Drugs; 2010 Mar;15(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging therapy for the treatment of acute lymphoblastic leukemia.
  • IMPORTANCE OF THE FIELD: Over the last few decades, advances in acute lymphoblastic leukemia (ALL) therapy have led to long-term survival rates of > 80% in children; however, comparable rates have yet to be achieved in adults, and a large majority of patients relapse from their disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational / therapeutic use. Neoplasm, Residual / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Aged. Child. Disease-Free Survival. Humans. Salvage Therapy / methods. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055690.001).
  • [ISSN] 1744-7623
  • [Journal-full-title] Expert opinion on emerging drugs
  • [ISO-abbreviation] Expert Opin Emerg Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 68
  •  go-up   go-down


32. Liu CY, Hsu YH, Wu MT, Pan PC, Ho CK, Su L, Xu X, Li Y, Christiani DC, Kaohsiung Leukemia Research Group: Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study. BMC Cancer; 2009 Jan 13;9:15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cured meat, vegetables, and bean-curd foods in relation to childhood acute leukemia risk: a population based case-control study.
  • This study investigated whether consumed cured/smoked meat and fish, the major dietary resource for exposure to nitrites and nitrosamines, is associated with childhood acute leukemia.
  • 145 acute leukemia cases and 370 age- and sex-matched controls were recruited between 1997 and 2005.
  • RESULTS: Consumption of cured/smoked meat and fish more than once a week was associated with an increased risk of acute leukemia (OR = 1.74; 95% CI: 1.15-2.64).
  • No statistically significant association was observed between leukemia risk and the consumption of pickled vegetables, fruits, and tea.
  • CONCLUSION: Dietary exposure to cured/smoked meat and fish may be associated with leukemia risk through their contents of nitrites and nitrosamines among children and adolescents, and intake of vegetables and soy-bean curd may be protective.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] IARC Monogr Eval Carcinog Risks Hum Suppl. 1987;7:1-440 [3482203.001]
  • [Cites] Toxicology. 2002 Dec 27;181-182:79-82 [12505288.001]
  • [Cites] Comp Biochem Physiol A Comp Physiol. 1989;93(1):285-90 [2568231.001]
  • [Cites] Cancer Res. 1989 Sep 15;49(18):5111-7 [2548712.001]
  • [Cites] J Natl Cancer Inst. 1991 Apr 17;83(8):541-6 [1672382.001]
  • [Cites] Cancer Causes Control. 1991 Nov;2(6):427-42 [1764568.001]
  • [Cites] Eur J Cancer Prev. 1993 Mar;2(2):139-46 [8461864.001]
  • [Cites] Nature. 1993 May 27;363(6427):358-60 [8497319.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):141-8 [8167261.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):195-202 [8167267.001]
  • [Cites] J Nutr. 1995 Mar;125(3 Suppl):790S-797S [7533831.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):901-6 [8922298.001]
  • [Cites] Blood. 1997 Jan 1;89(1):281-5 [8978302.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Radiat Environ Biophys. 1998 Feb;36(4):217-28 [9523337.001]
  • [Cites] Cancer Causes Control. 1998 Dec;9(6):553-7 [10189040.001]
  • [Cites] Am J Clin Nutr. 1999 Sep;70(3 Suppl):464S-474S [10479219.001]
  • [Cites] Am J Epidemiol. 2004 Dec 1;160(11):1098-107 [15561989.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):163-5 [15540221.001]
  • [Cites] Free Radic Biol Med. 2005 Jul 15;39(2):257-65 [15964517.001]
  • [Cites] Nutr Cancer. 2006;54(1):111-42 [16800779.001]
  • [Cites] Am J Epidemiol. 2006 Aug 1;164(3):200-7 [16754633.001]
  • [Cites] Nutr Cancer. 2006;56(2):225-31 [17474869.001]
  • [Cites] J Nutr. 2008 Apr;138(4):775-81 [18356334.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):984-90 [18339682.001]
  • [Cites] Am J Clin Nutr. 2008 Jul;88(1):176-84 [18614739.001]
  • [Cites] Am J Epidemiol. 1999 Nov 1;150(9):930-8 [10547138.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4411-3 [10781030.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):665-8 [12869409.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):667-71 [15158086.001]
  • [Cites] Free Radic Biol Med. 2004 Jun 15;36(12):1505-16 [15182853.001]
  • [Cites] Cancer Causes Control. 2004 Aug;15(6):559-70 [15280635.001]
  • [Cites] Ann N Y Acad Sci. 1980;355:267-79 [6940481.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1985;2(1):7-10 [3903369.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Int J Cancer. 2000 Jun 1;86(5):603-9 [10797279.001]
  • [Cites] J Nutr. 2000 Aug;130(8):1887-93 [10917898.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1051-8 [11045787.001]
  • [Cites] Free Radic Res. 2001 Sep;35(3):215-31 [11697121.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):777-81 [12163333.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):815-21 [12223424.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Mar;24(3):403-11 [3383943.001]
  • (PMID = 19144145.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES00002; United States / NIEHS NIH HHS / ES / ES09723
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2653540
  • [Investigator] Chang TT; Lin SF; Chiou SS; Jang RC; Hsiao HH; Liu TC; Lin PC; Hsiao CC; Sheen JM; Kuo CY; Wang MC; Huang CH; Huang CB; Wong YC; Wu HB; Lin SJ; Sun YM; Hsieh KS; Chang YH
  •  go-up   go-down


33. Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K, Taniguchi Y, Sekine M, Kamiunntenn A, Maeda K, Nagata K, Matsunaga T, Shimoda K: Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. Int J Hematol; 2010 Sep;92(2):320-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
  • Somatic JAK1 mutations are found in 18% of adult precursor T acute lymphoblastic leukemias and somatic JAK3 mutations are found in 3.3% of cutaneous T cell lymphomas.
  • Adult T cell leukemia/lymphoma (ATLL) is a type of T cell neoplasm, and activation of JAK/STAT pathways is sometimes observed in them.
  • [MeSH-major] Janus Kinase 1 / genetics. Janus Kinase 3 / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Adult. Cell Differentiation. Cell Proliferation. DNA Mutational Analysis. Humans. Japan. Polymorphism, Single Nucleotide

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunol Rev. 2009 Mar;228(1):273-87 [19290934.001]
  • [Cites] Science. 1994 Nov 11;266(5187):1042-5 [7973658.001]
  • [Cites] Cell. 1987 Jan 30;48(2):343-50 [3026643.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):387-97 [15837627.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14 (12 ):3716-21 [18559588.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1553-9 [16236609.001]
  • [Cites] Br J Haematol. 2007 May;137(4):337-41 [17456055.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):71-82 [14630083.001]
  • [Cites] J Exp Med. 2008 Apr 14;205(4):751-8 [18362173.001]
  • [Cites] Cell. 1998 May 1;93(3):373-83 [9590172.001]
  • [Cites] Eur J Haematol. 2002 Jun;68(6):362-9 [12225394.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] Leuk Lymphoma. 2001 Sep-Oct;42(5):1107-9 [11697628.001]
  • [Cites] Blood. 2008 May 1;111(9):4797-808 [18270328.001]
  • [Cites] Br J Haematol. 2008 May;141(5):681-8 [18397343.001]
  • [Cites] Science. 1995 Jul 7;269(5220):79-81 [7604283.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1309-12 [9360930.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2535-40 [9326218.001]
  • [Cites] Rev Med Virol. 2007 Sep-Oct;17 (5):301-11 [17621367.001]
  • [Cites] Science. 1995 Nov 3;270(5237):794-7 [7481767.001]
  • [Cites] Retrovirology. 2006 Apr 09;3:22 [16603085.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] J Leukoc Biol. 2008 Jan;83(1):220-2 [17962369.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):673-83 [17721432.001]
  • [Cites] J Virol. 1998 May;72 (5):4408-12 [9557732.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3770-4 [11325850.001]
  • [Cites] Immunity. 1995 Dec;3(6):771-82 [8777722.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(15):5389-93 [3037548.001]
  • [Cites] FEBS Lett. 1994 Oct 24;353(3):289-93 [7957877.001]
  • [Cites] Lancet. 2008 Oct 25;372(9648):1484-92 [18805579.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Blood. 2008 May 1;111(9):4809-12 [18160671.001]
  • [Cites] Int Rev Immunol. 2007 Sep-Dec;26(5-6):269-81 [18027201.001]
  • [Cites] Blood. 2009 Mar 19;113(12 ):2746-54 [19139084.001]
  • [Cites] Nature. 1994 Jul 14;370(6485):153-7 [8022486.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] Cancer Cell. 2006 Jul;10 (1):65-75 [16843266.001]
  • [Cites] Leuk Res. 1999 Apr;23 (4):373-84 [10229324.001]
  • [Cites] Cell. 1998 May 1;93(3):397-409 [9590174.001]
  • [Cites] J Immunol. 2007 Mar 1;178(5):2623-9 [17312100.001]
  • (PMID = 20697856.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 1; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


34. Olgar S, Yetgin S, Cetin M, Aras T: Can renal leukemic infiltration cause hypertension in children? J Pediatr Hematol Oncol; 2006 Sep;28(9):579-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Out of 334 children with acute lymphoblastic leukemia who were treated with St Jude Total XI and Total XIII chemotherapy protocols were investigated and 21 (6.3%) were hypertensive.
  • We found that renal leukemic infiltration is a risk factor in hypertension development (P = 0.04) and hypertension is a risk factor for renal parenchymal disorder in the follow-up period (P = 0.0001).
  • Six patients presenting with hypertension in the first week of disease therapy were evaluated for renal parenchymal disorder and glomerular filtration rate abnormality in the follow-up period.
  • Glomerular filtration rate abnormality was found in 1 and renal scintigraphic dimercaptosuccinic acid abnormalities (reduced uptake and dilated hypoactivity) were found in 4 patients.
  • Hypertension was also found to be a risk factor for renal parenchymal disorder in the follow-up period.
  • [MeSH-major] Hypertension, Renal / etiology. Kidney / pathology. Leukemic Infiltration / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17006264.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Nachman J: Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol; 2005 Jul;130(2):166-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia.
  • Young adult patients with acute lymphoblastic leukaemia (ALL) represent a unique epidemiologic subgroup in that therapy may be provided by either adult or paediatric oncologists.
  • 21) hyperdiploidy, a slightly increased incidence of the t(9;22), and an increased frequency of T cell immunophenotype.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029445.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


36. Nowak NJ, Sait SN, Zeidan A, Deeb G, Gaile D, Liu S, Ford L, Wallace PK, Wang ES, Wetzler M: Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2010 May;199(1):15-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia.
  • The prognosis of adult normal karyotype (NK) precursor B-cell acute lymphoblastic leukemia (B-ALL) has not improved over the last decade, mainly because separation into distinct molecular subsets has been lacking and no targeted treatments are available.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • [Cites] Mol Biol Cell. 2000 Oct;11(10):3381-96 [11029043.001]
  • [Cites] J Hematol Oncol. 2009;2:3 [19166587.001]
  • [Cites] Nat Genet. 2001 Nov;29(3):263-4 [11687795.001]
  • [Cites] Blood. 2002 Jan 1;99(1):252-7 [11756179.001]
  • [Cites] Eur J Haematol. 2003 Jun;70(6):363-72 [12756018.001]
  • [Cites] Int Immunol. 2004 Oct;16(10):1377-89 [15302850.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] Haematologica. 2007 Feb;92(2):232-5 [17296573.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Genet Med. 2007 Sep;9(9):585-95 [17873646.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):572-7 [18275435.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1030-43 [18358930.001]
  • [Cites] Curr Protoc Hum Genet. 2005 Aug;Chapter 4:Unit 4.13 [18428377.001]
  • [Cites] Blood. 2008 May 1;111(9):4668-80 [18299449.001]
  • [Cites] Leuk Res. 2008 Aug;32(8):1228-35 [18328560.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 May 6;105(18):6708-13 [18458336.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):400-7 [18536580.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Sep;14(3):593-607 [11640871.001]
  • (PMID = 20417863.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; None / None / / P30 CA016056-33; United States / NCI NIH HHS / CA / CA16056; United States / NCI NIH HHS / CA / P30 CA016056-33
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 157907-48-7 / HoxA protein
  • [Other-IDs] NLM/ NIHMS173834; NLM/ PMC2862995
  •  go-up   go-down


37. Hildebrandt P, Richards AM: Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension. Am J Cardiol; 2008 Feb 4;101(3A):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amino-terminal pro-B-type natriuretic peptide testing in patients with diabetes mellitus and with systemic hypertension.
  • Although the current value of amino-terminal pro-B-type natriuretic peptides (NT-proBNP) to generally screen populations of "apparently well patients" remains promising but still undefined, the use of NT-proBNP to screen patients at high risk for heart disease (such as elderly patients, or patients with diabetes mellitus, hypertension, or known coronary artery disease) appears logical and is supported by data.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243853.001).
  • [ISSN] 0002-9149
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Peptide Fragments; 0 / Protein Precursors; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  • [Number-of-references] 19
  •  go-up   go-down


38. Mansha M, Carlet M, Ploner C, Gruber G, Wasim M, Wiegers GJ, Rainer J, Geley S, Kofler R: Functional analyses of Src-like adaptor (SLA), a glucocorticoid-regulated gene in acute lymphoblastic leukemia. Leuk Res; 2010 Apr;34(4):529-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional analyses of Src-like adaptor (SLA), a glucocorticoid-regulated gene in acute lymphoblastic leukemia.
  • Glucocorticoids (GCs) cause apoptosis and cell cycle arrest in lymphoid cells and are used in the therapy of lymphoid malignancies.
  • SLA (Src-like-adaptor), an inhibitor of T- and B-cell receptor signaling, is a promising candidate derived from expression profiling analyses in children with acute lymphoblastic leukemia (ALL).
  • Over-expression and knock-down experiments in ALL in vitro model revealed that transgenic SLA alone had no effect on survival or cell cycle progression, nor did it affect sensitivity to, or kinetics of, GC-induced apoptosis.
  • [MeSH-major] Adaptor Proteins, Signal Transducing / genetics. Adaptor Proteins, Signal Transducing / physiology. Gene Expression Regulation, Leukemic / drug effects. Glucocorticoids / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins pp60(c-src) / genetics. Proto-Oncogene Proteins pp60(c-src) / physiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXYCYCLINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19631983.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18571; Austria / Austrian Science Fund FWF / / P 18747; Austria / Austrian Science Fund FWF / / W 1101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antineoplastic Agents; 0 / Glucocorticoids; 0 / RNA, Small Interfering; 0 / SLA protein, human; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src); N12000U13O / Doxycycline
  •  go-up   go-down


39. Li L, Liu LN, Feller S, Allen C, Shivakumar R, Fratantoni J, Wolfraim LA, Fujisaki H, Campana D, Chopas N, Dzekunov S, Peshwa M: Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther; 2010 Mar;17(3):147-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NK cytotoxicity can be enhanced by expression of chimeric antigen receptors that re-direct specificity toward target cells by engaging cell surface molecules expressed on target cells.
  • We developed a regulatory-compliant, scalable non-viral approach to engineer NK cells to be target-specific based on transfection of mRNA encoding chimeric receptors.
  • Transfection of eGFP mRNA into ex vivo expanded NK cells (N=5) or purified unstimulated NK cells from peripheral blood (N=4) resulted in good cell viability with eGFP expression in 85+/-6% and 86+/-4%, 24 h after transfection, respectively.
  • Ex vivo expanded and purified unstimulated NK cells expressing anti-CD19-BB-z exhibited enhanced cytotoxicity against CD19(+) target cells resulting in > or =80% lysis of acute lymphoblastic leukemia and B-lineage chronic lymphocytic leukemia cells at effector target ratios lower than 10:1.
  • The target-specific cytotoxicity for anti-CD19-BB-z mRNA-transfected NK cells was observed as early as 3 h after transfection and persisted for up to 3 days.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2003 Mar 1;274(1-2):245-56 [12609550.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1935-47 [12200350.001]
  • [Cites] J Immunol Methods. 2003 Nov;282(1-2):93-102 [14604544.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):104-13 [14688315.001]
  • [Cites] J Immunol Methods. 2004 Jan;284(1-2):133-40 [14736423.001]
  • [Cites] Leukemia. 2004 Apr;18(4):676-84 [14961035.001]
  • [Cites] Methods. 2004 Jun;33(2):126-35 [15121167.001]
  • [Cites] Exp Hematol. 2004 Jun;32(6):536-46 [15183894.001]
  • [Cites] Curr Hematol Rep. 2005 Jan;4(1):64-72 [15610662.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Feb 4;327(1):356-60 [15629470.001]
  • [Cites] Blood. 2005 Apr 15;105(8):3051-7 [15632206.001]
  • [Cites] Blood. 2005 Jul 1;106(1):376-83 [15755898.001]
  • [Cites] Cytotherapy. 2005;7(1):16-22 [16040380.001]
  • [Cites] Mol Ther. 2006 Jan;13(1):151-9 [16140584.001]
  • [Cites] Cancer Gene Ther. 2006 Feb;13(2):215-24 [16082377.001]
  • [Cites] Haematologica. 2006 Apr;91(4):513-21 [16533723.001]
  • [Cites] Cytotherapy. 2006;8(2):105-17 [16698684.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1835-8 [15457184.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 1986;105:176-256 [3541139.001]
  • [Cites] Biophys J. 1990 Jul;58(1):13-9 [2200534.001]
  • [Cites] Blood. 1994 Apr 1;83(7):1731-7 [8142640.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(11):1057-63 [9877267.001]
  • [Cites] Adv Exp Med Biol. 1998;452:13-8 [9889954.001]
  • [Cites] Cancer Invest. 2006 Apr-May;24(3):302-9 [16809159.001]
  • [Cites] Leukemia. 2006 Oct;20(10):1819-28 [16932339.001]
  • [Cites] Hum Gene Ther. 2006 Oct;17(10):1027-35 [17007566.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10995-1004 [17108138.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4009-17 [16940422.001]
  • [Cites] Curr Opin Oncol. 2007 Mar;19(2):142-7 [17272987.001]
  • [Cites] Transfusion. 2007 Mar;47(3):520-8 [17319835.001]
  • [Cites] Haematologica. 2007 Mar;92(3):381-8 [17339188.001]
  • [Cites] J Leukoc Biol. 2007 Oct;82(4):849-60 [17626798.001]
  • [Cites] Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35 [17855649.001]
  • [Cites] Handb Exp Pharmacol. 2008;(181):329-42 [18071952.001]
  • [Cites] Mol Immunol. 2008 Apr;45(8):2255-61 [18243319.001]
  • [Cites] Exp Cell Res. 1999 Dec 15;253(2):541-50 [10585278.001]
  • [Cites] Gene Ther. 2000 Aug;7(16):1431-7 [10981672.001]
  • [Cites] Bone Marrow Transplant. 2000 Sep;26(5):511-6 [11019840.001]
  • [Cites] FASEB J. 2001 Mar;15(3):586-8 [11259375.001]
  • [Cites] J Hematother Stem Cell Res. 2001 Aug;10(4):451-63 [11522229.001]
  • [Cites] Nat Med. 2001 Oct;7(10):1155-8 [11590441.001]
  • [Cites] Science. 2002 Mar 15;295(5562):2097-100 [11896281.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):252-8 [12110902.001]
  • [Cites] Technol Cancer Res Treat. 2002 Oct;1(5):341-50 [12625759.001]
  • (PMID = 19745843.001).
  • [ISSN] 1476-5500
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113482-04; United States / NCI NIH HHS / CA / R01 CA113482; United States / NCI NIH HHS / CA / R01 CA113482-04
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Receptors, Antigen; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ NIHMS154275; NLM/ PMC2821468
  •  go-up   go-down


40. Rabin KR, Man TK, Yu A, Folsom MR, Zhao YJ, Rao PH, Plon SE, Naeem RC: Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Aug;51(2):171-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of array comparative genomic hybridization for detection of chromosomal abnormalities in pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Accurate detection of recurrent chromosomal abnormalities is critical to assign patients to risk-based therapeutic regimens for pediatric acute lymphoblastic leukemia (ALL).

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 1995 May;13(1):54-61 [7541644.001]
  • [Cites] Leukemia. 2004 May;18(5):939-47 [14999294.001]
  • [Cites] Cancer Genet Cytogenet. 1998 May;103(1):20-4 [9595040.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3413-22 [15381628.001]
  • [Cites] J Med Genet. 2005 Feb;42(2):121-8 [15689449.001]
  • [Cites] Br J Haematol. 2005 May;129(4):520-30 [15877734.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Genes Chromosomes Cancer. 2006 May;45(5):482-94 [16425296.001]
  • [Cites] Br J Haematol. 2006 Nov;135(4):492-9 [16999846.001]
  • [Cites] J Mol Diagn. 2006 Nov;8(5):528-33 [17065418.001]
  • [Cites] PLoS One. 2007;2(3):e327 [17389918.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Sep;46(9):805-12 [17539022.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1613-9 [7564498.001]
  • [CommentIn] Pediatr Blood Cancer. 2008 Aug;51(2):153-4 [18300321.001]
  • (PMID = 18253961.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA090433; United States / NCI NIH HHS / CA / CA90433-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS570929; NLM/ PMC4063297
  •  go-up   go-down


41. Luria D, Rosenthal E, Steinberg D, Kodman Y, Safanaiev M, Amariglio N, Avigad S, Stark B, Izraeli S, Israel National Study Group of Childhood ALL: Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia. Cytometry B Clin Cytom; 2010 Nov;78(6):365-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective comparison of two flow cytometry methodologies for monitoring minimal residual disease in a multicenter treatment protocol of childhood acute lymphoblastic leukemia.
  • BACKGROUND: Minimal residual disease (MRD) is a powerful prognostic indicator in childhood acute lymphoblastic leukemia (ALL).
  • A total of 290 samples at diagnosis and 494 follow-up samples (Day-15 n = 261; Day-33 n = 233) were analyzed.
  • [MeSH-major] Flow Cytometry / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Humans. Neoplasm, Residual / diagnosis. Neoplasm, Residual / drug therapy. Prospective Studies

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 International Clinical Cytometry Society.
  • (PMID = 20632326.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Dina A; Gali A; Ami B; Bella B; Yoav B; Ronit E; Herzel G; Yosef K; Hagit M; Dalia S; Michael W
  •  go-up   go-down


42. Handrup MM, Møller JK, Frydenberg M, Schrøder H: Placing of tunneled central venous catheters prior to induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2010 Aug;55(2):309-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placing of tunneled central venous catheters prior to induction chemotherapy in children with acute lymphoblastic leukemia.
  • BACKGROUND: Tunneled central venous catheters (CVCs) are inevitable in children with acute lymphoid leukemia (ALL).
  • The aim of this study was to evaluate the risk of CVC-related complications in children with ALL in relation to timing of catheter placement and type of catheter.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Catheter-Related Infections / etiology. Catheterization, Central Venous / adverse effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20582964.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Elmantaser M, Stewart G, Young D, Duncan R, Gibson B, Ahmed SF: Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Arch Dis Child; 2010 Oct;95(10):805-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia.
  • BACKGROUND: Children receiving chemotherapy for acute lymphoblastic leukaemia (ALL) may be susceptible to skeletal morbidity.
  • The median (10th, 90th centiles) age at diagnosis of ALL in those children without skeletal morbidity was 3.9 (1.4-12) years which was lower than in those with skeletal morbidity at 8.2 (2.2-14.3) years (p<0.00001, 95% CI 1.7 to 4.4).
  • CONCLUSION: The occurrence of skeletal morbidity in ALL children may be influenced by age and the type of glucocorticoids.
  • [MeSH-major] Bone Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576660.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


44. Peterson CC, Johnson CE, Ramirez LY, Huestis S, Pai AL, Demaree HA, Drotar D: A meta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer; 2008 Jul;51(1):99-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia.
  • BACKGROUND: Mixed findings on the neuropsychological sequelae of chemotherapy-only treatment for pediatric acute lymphoblastic leukemia (ALL), without radiation, indicate the need for a comprehensive meta-analytic review.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Neuropsychological Tests. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18322925.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


45. Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van Dongen JJ, Veerman AJ, van Leeuwen FN, van Kessel AG, Hoogerbrugge PM: IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia; 2010 Jul;24(7):1258-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.
  • Relapse is the most common cause of treatment failure in pediatric acute lymphoblastic leukemia (ALL) and is often difficult to predict.
  • To explore the prognostic impact of recurrent DNA copy number abnormalities on relapse, we performed high-resolution genomic profiling of 34 paired diagnosis and relapse ALL samples.
  • Recurrent lesions detected at diagnosis, including PAX5, CDKN2A and EBF1, were frequently absent at relapse, indicating that they represent secondary events that may be absent in the relapse-prone therapy-resistant progenitor cell.
  • A targeted copy number screen in an unselected cohort of 131 precursor B-ALL cases, enrolled in the dexamethasone-based Dutch Childhood Oncology Group treatment protocol ALL9, revealed that IKZF1 deletions are significantly associated with poor relapse-free and overall survival rates.
  • Consequently, IKZF1 deletion status allowed the prospective identification of 53% of the relapse-prone NHR-classified patients within this subgroup and, therefore, serves as one of the strongest predictors of relapse at the time of diagnosis with high potential for future risk stratification.
  • [MeSH-major] Gene Deletion. Ikaros Transcription Factor / genetics. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics


46. Kiss F, Hevessy Z, Veszprémi A, Katona E, Kiss C, Vereb G, Muszbek L, Kappelmayer JN: Leukemic lymphoblasts, a novel expression site of coagulation factor XIII subunit A. Thromb Haemost; 2006 Aug;96(2):176-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intracellular dimeric form of FXIII (A2) is present in platelets, megakaryocytes, monocytes and macrophages and has been detected in mono- and megakaryocytic leukemias.
  • The aim of our study was to investigate FXIII-A expression in newly diagnosed B cell acute lymphoblastic leukemia (ALL) samples.
  • We examined 47 de novo ALL cases of B cell origin by triple color labeling with flow cytometry.
  • Antigen concentration was 3.11 +/- 1.19 fg/blast, while normal lymphoid precursors and mature lymphocytes from B-CLL did not contain FXIII-A.
  • [MeSH-major] Factor XIII / chemistry. Gene Expression Regulation, Neoplastic. Leukemia / metabolism. Lymphocytes / metabolism

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894461.001).
  • [ISSN] 0340-6245
  • [Journal-full-title] Thrombosis and haemostasis
  • [ISO-abbreviation] Thromb. Haemost.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 104641-95-4 / factor XIII subunit A; 9013-56-3 / Factor XIII
  •  go-up   go-down


47. Kabbara N, Lacroix C, Peffault de Latour R, Socié G, Ghannoum M, Ribaud P: Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica; 2008 Apr;93(4):639-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy.
  • [MeSH-major] Antifungal Agents / therapeutic use. Candida / isolation & purification. Candidiasis / etiology. Echinocandins / therapeutic use. Fungemia / etiology. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Anemia, Aplastic / complications. Anemia, Aplastic / surgery. Fluconazole / administration & dosage. Fluconazole / therapeutic use. Humans. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / surgery. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery. Premedication. Retrospective Studies. Transplantation, Homologous. Treatment Failure

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • Hazardous Substances Data Bank. FLUCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379015.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 8VZV102JFY / Fluconazole; F0XDI6ZL63 / caspofungin
  •  go-up   go-down


48. Sandlund JT, Howard SC, Hijiya N, Pui CH, Shenep JL, Adderson EE: Myositis complicating viridans streptococcal sepsis in childhood leukemia. Pediatr Blood Cancer; 2005 Mar;44(3):277-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myositis complicating viridans streptococcal sepsis in childhood leukemia.
  • We describe two patients with acute leukemia who developed myositis during alpha-hemolytic streptococcal bacteremia.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Myositis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Streptococcal Infections / complications. Viridans Streptococci

  • Genetic Alliance. consumer health - Myositis.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Myositis.
  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15468304.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


49. Comeau TB, Phillips DL: Chemotherapy dosing with elevated liver function test results in acute leukemia. Ann Pharmacother; 2005 Oct;39(10):1752-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy dosing with elevated liver function test results in acute leukemia.
  • OBJECTIVE: To report a case of massive blast infiltration of the liver by acute lymphoblastic leukemia (ALL) manifested by worsening liver function test (LFT) results and concern over how to dose chemotherapy in this patient.
  • CASE SUMMARY: A 36-year-old male presenting with productive cough, abdominal pain, and lower back pain was diagnosed with pre-B cell ALL.
  • Of note, the patient developed worsening LFT results within the first few days of diagnosis.
  • CONCLUSIONS: It is important to discern the cause of elevated LFT values in patients with acute leukemia who require induction chemotherapy, as this may affect treatment decisions and patient outcomes.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Liver / physiopathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adult. Daunorubicin / administration & dosage. Daunorubicin / adverse effects. Daunorubicin / therapeutic use. Humans. Liver Function Tests. Male. Prednisone / administration & dosage. Prednisone / adverse effects. Prednisone / therapeutic use. Vincristine / administration & dosage. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16131538.001).
  • [ISSN] 1060-0280
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


50. Linabery AM, Blair CK, Gamis AS, Olshan AF, Heerema NA, Ross JA: Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2572-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study.
  • Children with Down syndrome, due to their heightened risk of leukemia and increased prevalence of congenital abnormalities, comprise a valuable population in which to study etiology.
  • A Children's Oncology Group study investigated the causes of childhood leukemia in children with Down syndrome diagnosed at ages 0 to 19 years during the period 1997-2002.
  • Telephone interviews were completed with mothers of 158 cases [n=97 acute lymphoblastic leukemia (ALL) and n=61 acute myeloid leukemia (AML)] and 173 controls.
  • Odds ratios (OR) and 95% confidence intervals (95% CI) were computed via unconditional logistic regression to evaluate the association between congenital abnormalities and acute leukemia overall, and ALL and AML analyzed separately.
  • The results do not provide evidence for an association among the index children (OR(Combined), 0.74; 95% CI, 0.45-1.23; OR(ALL), 0.67; 95% CI, 0.38-1.20; OR(AML),1.03; 95% CI, 0.49-2.16) or their siblings (OR(Combined), 1.23; 95% CI, 0.71-2.13; OR(ALL), 1.12; 95% CI, 0.60-2.09; OR(AML), 1.60; 95% CI, 0.66-3.86), suggesting congenital malformations do not confer additional risk of leukemia beyond the risk attributable to trisomy 21 in this population.

  • Genetic Alliance. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Birth Defects.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Hematol Oncol. 1987;4(3):211-30 [2978961.001]
  • [Cites] Am J Hum Genet. 1990 Mar;46(3):478-85 [2309699.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Mar-Apr;23(3):175-8 [11305722.001]
  • [Cites] Int J Epidemiol. 2001 Apr;30(2):350-2 [11369741.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2001 Dec 1;61(3):199-205 [11700189.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1339-45 [12599243.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):162-74 [15313588.001]
  • [Cites] Cancer Res. 1991 Jul 15;51(14):3696-701 [2065325.001]
  • [Cites] Leukemia. 1992;6 Suppl 1:5-7 [1532221.001]
  • [Cites] Am J Epidemiol. 1993 Mar 15;137(6):629-38 [8470664.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):357-63 [8347491.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):201-7 [8630931.001]
  • [Cites] Am J Hum Genet. 1997 Mar;60(3):474-85 [9042906.001]
  • [Cites] Am J Med Genet. 1998 Jan 6;75(1):22-7 [9450852.001]
  • [Cites] Am J Med Genet. 1998 Jun 5;77(5):431-8 [9632176.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1244-9 [9820188.001]
  • [Cites] J Pediatr. 1998 Nov;133(5):617-23 [9821417.001]
  • [Cites] Arch Dis Child. 1999 Jan;80(1):1-3 [10325750.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):8-12 [15390275.001]
  • [Cites] Cancer. 2005 May 1;103(9):1939-48 [15770693.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):405-10 [15952191.001]
  • [Cites] J Pediatr Health Care. 2006 Jan-Feb;20(1):47-54 [16399479.001]
  • [Cites] Nature. 2006 Jun 1;441(7093):595-600 [16554754.001]
  • [Cites] Pediatrics. 2006 Nov;118(5):e1499-508 [17030598.001]
  • [Cites] Curr Opin Pediatr. 2007 Feb;19(1):9-14 [17224656.001]
  • [Cites] JAMA. 2008 Jan 2;299(1):61-9 [18167407.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):500-6 [18296646.001]
  • [Cites] Lancet. 1981 Nov 7;2(8254):1020-2 [6118480.001]
  • [Cites] Dev Med Child Neurol. 1982 Dec;24(6):817-29 [6218002.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • (PMID = 18829445.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA016086-259036; United States / NIEHS NIH HHS / ES / P30 ES10126; United States / NCI NIH HHS / CA / T32 CA099936-01A1; United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / R01 CA075169-03; United States / NCI NIH HHS / CA / P30 CA016086; United States / NCI NIH HHS / CA / R01 CA075169; United States / NCI NIH HHS / CA / R01 CA75169; United States / NCI NIH HHS / CA / CA075169-03; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / P30 CA016086-259036; United States / NCI NIH HHS / CA / CA099936-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS78459; NLM/ PMC2610427
  •  go-up   go-down


51. Shin HJ, Chung JS, Cho GJ: Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant; 2005 Nov;36(10):917-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • [MeSH-major] Bone Marrow Purging / methods. Hematopoietic Stem Cell Transplantation / methods. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Female. Humans. Imatinib Mesylate. Neoplasm, Residual / diagnosis. Neoplasm, Residual / drug therapy. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113662.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


52. Yasmeen N, Ashraf S: Childhood acute lymphoblastic leukaemia; epidemiology and clinicopathological features. J Pak Med Assoc; 2009 Mar;59(3):150-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute lymphoblastic leukaemia; epidemiology and clinicopathological features.
  • OBJECTIVE: To study epidemiology, clinical presentation and laboratory features of childhood Acute Lymphoblastic Leukaemia.
  • METHOD: This retrospective review included all newly diagnosed children with acute lymphoblastic Leukaemia less than 15 years of age registered from April 1999 to December 2004 at oncology unit of National Institute of Child Health and Children Cancer Hospital, Karachi.
  • RESULTS: Acute lymphoblastic Leukaemia constituted 32% (611 /1890) of all cancers in this study.
  • Fever and pallor were the commonest presenting features.
  • Anaemia (86%), lymphadenopathy (75%) hepatomegaly (67%) and splenomegly (58%) were common findings on physical examination.
  • Initial high white cell count (> 50,000) was observed in 34% patients.
  • CNS disease was present in 5% and HBsAg was positive in 14% patients at diagnosis.
  • CONCLUSION: Acute Lymphoblastic Leukaemia accounts for one third of total registered cases.
  • The fraction with a WBC count above 50,000 mm3 (30%), a higher proportion with lymphadenopathy (75%) and haemoglobin less than 7 gm/dl (54%) suggest that Pakistani children have significantly higher burdens of Leukaemia cells at presentation.
  • These may have prognostic implication resulting in poor outcome of Leukaemia in this part of the world.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology
  • [MeSH-minor] Acute Disease. Adolescent. Age Distribution. Age Factors. Child. Child, Preschool. Female. Histocytochemistry. Humans. Immunophenotyping. Infant. Leukocyte Count. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288940.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


53. Williams LE, Pruitt AF, Thrall DE: Chemotherapy followed by abdominal cavity irradiation for feline lymphoblastic lymphoma. Vet Radiol Ultrasound; 2010 Nov-Dec;51(6):681-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy followed by abdominal cavity irradiation for feline lymphoblastic lymphoma.
  • The goal of this prospective pilot study was to determine the normal tissue tolerance to 15 Gy total abdomen fractionated radiation therapy following induction chemotherapy in cats with lymphoblastic lymphoma.
  • Eight cats with lymphoblastic gastrointestinal or multicentric lymphoma confined to the abdominal cavity were treated with a 6-week combination chemotherapy protocol followed 2 weeks later by whole-abdomen radiation therapy consisting of 10 daily fractions of 1.5 Gy.
  • [MeSH-major] Abdominal Neoplasms / veterinary. Cat Diseases / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / veterinary

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21158247.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Pérez-Vera P, Montero-Ruiz O, Frías S, Ulloa-Avilés V, Cárdenas-Cardós R, Paredes-Aguilera R, Rivera-Luna R, Carnevale A: Detection of ETV6 and RUNX1 gene rearrangements using fluorescence in situ hybridization in Mexican patients with acute lymphoblastic leukemia: experience at a single institution. Cancer Genet Cytogenet; 2005 Oct 15;162(2):140-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of ETV6 and RUNX1 gene rearrangements using fluorescence in situ hybridization in Mexican patients with acute lymphoblastic leukemia: experience at a single institution.
  • Due to the prevalence of RUNX1 overrepresentation in our population and its unknown prognostic significance, further studies should be conducted in consecutive children with ALL, to correlate this abnormality with the patients' follow-up.
  • [MeSH-major] Gene Rearrangement. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213362.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ETS translocation variant 6 protein; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins
  •  go-up   go-down


55. İrken G, Ören H, Öniz H, Çetingül N, Vergin C, Atabay B, Gülen H, Türker M, Kantar M, Yılmaz Ş: Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome. Turk J Haematol; 2006 Sep 5;23(3):142-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleukocytosis in childhood acute lymphoblastic leukemia: complications and treatment outcome.
  • Hyperleukocytosis, defined as a peripheral leukocyte count ≥ 100x109/L, is seen in 5-20% of newly diagnosed cases of childhood leukemia and is a poor prognostic factor.
  • In this study, we aimed to examine the presenting clinical and laboratory features, complications, and treatment outcome of 47 children with acute lymphoblastic leukemia (ALL) and hyperleukocytosis who were diagnosed and treated in four medical centers of İzmir between January 1990 and January 2001.
  • Median white blood cell count was 495x109/L (range: 107x109/L- 794x109/L).
  • Forty-two of 47 patients (90%) had hepatosplenomegaly, 5 (11%) had respiratory distress, 3 (6%) had neurologic symptoms, 3 (6%) had diffuse cervical lymphadenopathy, and 3 (6%) had acute renal failure at admission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265481.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


56. Guo W, Lasky JL, Chang CJ, Mosessian S, Lewis X, Xiao Y, Yeh JE, Chen JY, Iruela-Arispe ML, Varella-Garcia M, Wu H: Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature; 2008 May 22;453(7194):529-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation.
  • Cancer stem cells, which share many common properties and regulatory machineries with normal stem cells, have recently been proposed to be responsible for tumorigenesis and to contribute to cancer resistance.
  • Here we show that Pten deletion in mouse haematopoietic stem cells leads to a myeloproliferative disorder, followed by acute T-lymphoblastic leukaemia (T-ALL).
  • Self-renewable leukaemia stem cells (LSCs) are enriched in the c-Kit(mid)CD3(+)Lin(-) compartment, where unphosphorylated beta-catenin is significantly increased.


57. Heinsohn S, Golta S, Kabisch H, zur Stadt U: Standardized detection of Simian virus 40 by real-time quantitative polymerase chain reaction in pediatric malignancies. Haematologica; 2005 Jan;90(1):94-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVES: Recent studies have detected Simian virus 40 (SV40) DNA in specific human tumors albeit with significant discrepancies in frequency.
  • A standardized and common detection method is, therefore, essential for further routine SV40 analysis.
  • We used 500 ng of the COS-1 cell line, containing one single integrated copy of SV40 DNA, as the quantification standard.
  • DNA samples from 149 healthy controls, from 26 fresh frozen childhood cases of acute lymphoblastic leukemia (ALL) (B-, BCP- and T-ALL) and from 12 paraffin-embedded osteosarcomas were investigated.
  • [MeSH-major] Osteosarcoma / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / virology. Simian virus 40 / isolation & purification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Haematologica. 2005 Jan;90(1):6 [15644307.001]
  • (PMID = 15642675.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


58. Bhardwaj A, Rehman SU, Mohammed A, Baggish AL, Moore SA, Januzzi JL Jr: Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. Am Heart J; 2010 Apr;159(4):532-538.e1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study.
  • BACKGROUND: Serial measurements of N-terminal pro-B type natriuretic peptide (NT-proBNP) provide prognostic information in patients with chronic heart failure (HF).
  • CONCLUSIONS: The Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study will test the hypothesis that therapy guided by NT-proBNP concentrations will be superior to standard of care HF management (www.clinicaltrials.gov identifier NCT00351390).

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20362709.001).
  • [ISSN] 1097-6744
  • [Journal-full-title] American heart journal
  • [ISO-abbreviation] Am. Heart J.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00351390
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / pro-brain natriuretic peptide (1-76); 114471-18-0 / Natriuretic Peptide, Brain
  •  go-up   go-down


59. Mandac I, Kolonić SO, Vrhovac R, Lasan-Trcić R, Jakelić-Pitesa J, Kardum-Skelin I: T-lymphoblastic lymphoma with an unusual t(8;14)(q24;q11)--case report. Coll Antropol; 2010 Mar;34(1):265-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-lymphoblastic lymphoma with an unusual t(8;14)(q24;q11)--case report.
  • Cytogenetic abnormalities seen at presentation of acute lymphoblastic leukemia or lymphoblastic lymphoma (ALL/ LBL) are associated with distinct clinical and hematologic disease entities.
  • Flow cytometry of lymph node revealed T cell phenotype of immature cells: CD45+CD2+CD5+CD7+CD4+CD8+CD3cyt +CD3TdT+CD10-CD34-HLAD/DR-.
  • Southern blot analysis of extracted DNA from the supraclavicular lymph node demonstrated clonal rearrangement of the T cell antigen receptor (TCR/J) gene (region Vb+Jb2).
  • Based on these findings, diagnosis of T lymphoblastic non Hodgkin lymphoma was established.
  • T-ALL/LBL with an unusual t(8;14)(q24;q11.2) is a very rare hematologic disorder with rapid disease progression and poor response to conventional therapy because of frequent central nervous system involvement and early relapses.
  • [MeSH-major] Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20432760.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


60. Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, Velasco C, Cole J, Rodriguez PC: Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood; 2010 Jun 24;115(25):5214-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adult patients with acute lymphoblastic T cell leukemia (T-ALL) have a very poor prognosis and few effective therapeutic options.
  • In addition, treatment of malignant T-cell lines with peg-Arg I significantly impaired their proliferation, which correlated with a decreased progression into the cell cycle, followed by the induction of apoptosis.
  • The results suggest the potential benefit of L-Arginine depletion by peg-Arg I in the treatment of T-cell malignancies.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2007 Feb 15;109(4):1568-73 [17023580.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):309-17 [17210712.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1553-60 [19201693.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1689-98 [19001083.001]
  • [Cites] Cancer Lett. 2009 May 8;277(1):91-100 [19138817.001]
  • [Cites] Nat Rev Mol Cell Biol. 2009 Jun;10(6):430-6 [19461665.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1215-24 [10914545.001]
  • [Cites] Trends Genet. 2000 Oct;16(10):469-73 [11050335.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1986-94 [11877270.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4843-8 [12655043.001]
  • [Cites] Trends Immunol. 2003 Jun;24(6):302-6 [12810105.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1232-9 [12874210.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):451-61 [14706337.001]
  • [Cites] Cell Death Differ. 2004 Apr;11(4):381-9 [14685163.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2004 Jan;7(1):45-51 [15090903.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1815-22 [15143074.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5839-49 [15313928.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5335-41 [15328169.001]
  • [Cites] J Nutr. 2004 Oct;134(10 Suppl):2760S-2764S; discussion 2765S-2767S [15465781.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Cancer Res. 1979 Oct;39(10):3893-6 [383278.001]
  • [Cites] Leuk Res. 1992;16(5):475-83 [1625473.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):70-82 [9045306.001]
  • [Cites] N Engl J Med. 1998 Aug 27;339(9):605-15 [9718381.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):318-27 [15803138.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3044-8 [15833831.001]
  • [Cites] Cell Immunol. 2004 Nov-Dec;232(1-2):21-31 [15922712.001]
  • [Cites] Nat Rev Immunol. 2005 Aug;5(8):641-54 [16056256.001]
  • [Cites] J Exp Med. 2005 Oct 3;202(7):931-9 [16186186.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7660-8 [16234528.001]
  • [Cites] Cell. 2006 Jun 16;125(6):1111-24 [16777601.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2768-72 [17986863.001]
  • (PMID = 20407034.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20RR021970; United States / NCRR NIH HHS / RR / P20 RR021970; United States / NCI NIH HHS / CA / R01 CA082689; United States / NIGMS NIH HHS / GM / P20 GM103501; United States / NCI NIH HHS / CA / R01 CA107974
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CCND3 protein, human; 0 / Cyclin D3; 04079A1RDZ / Cytarabine; 30IQX730WE / Polyethylene Glycols; 94ZLA3W45F / Arginine; EC 3.5.3.1 / Arginase
  • [Other-IDs] NLM/ PMC2892956
  •  go-up   go-down


61. Russo V, Scott IU, Querques G, Stella A, Barone A, Delle Noci N: Orbital and ocular manifestations of acute childhood leukemia: clinical and statistical analysis of 180 patients. Eur J Ophthalmol; 2008 Jul-Aug;18(4):619-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital and ocular manifestations of acute childhood leukemia: clinical and statistical analysis of 180 patients.
  • PURPOSE: To investigate the association between presence of orbital or ocular lesions and type and stage of leukemia and to investigate whether orbital and ocular lesions are significant in predicting leukemia prognosis.
  • METHODS: The authors evaluated 180 patients with acute childhood leukemia.
  • Lesions associated with leukemia may be classified as specific (due to leukemic infiltration of various ocular tissues), nonspecific (due to one of the secondary complications), or iatrogenic manifestations caused by chemotherapy.
  • Risk-based treatment assignment is based on clinical and laboratory features at diagnosis.
  • Children with presenting white blood cell count below 50,000 mm3 are considered at standard risk for treatment failure, while all others are considered at high risk for treatment failure.
  • RESULTS: Specific lesions were noted in 66% of patients with acute myeloid leukemia (AML) and 11.5% patients with acute lymphocytic leukemia (ALL) (p<0.05), and were more severe in patients with high risk leukemia than in patients with standard risk leukemia.
  • In both the AML and ALL groups, there was a higher frequency of leukemic relapses in the bone marrow and/or central nervous system in patients with specific lesions (63.1%) compared to patients with nonspecific lesions (42%), and in patients without orbital or ocular lesions (29.2%) (p<0.05).
  • CONCLUSIONS: In both the AML and ALL groups, the presence of specific orbital or ocular lesions was associated with a higher frequency of bone marrow relapses and CNS involvement (p<0.05), leading to a lower survival rate.
  • [MeSH-major] Eye Neoplasms / pathology. Leukemia, Myeloid, Acute / pathology. Leukemic Infiltration / pathology. Orbital Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18609485.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Podda L, Fozza C, Nieddu R, Sanna S, Paglietti B, Vacca A, La Nasa G, Longinotti M: Breakthrough cutaneous alternariosis in a patient with acute lymphoblastic leukemia: clinical features and diagnostic issues. Leuk Lymphoma; 2008 Jan;49(1):154-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breakthrough cutaneous alternariosis in a patient with acute lymphoblastic leukemia: clinical features and diagnostic issues.
  • [MeSH-major] Alternaria. Mycoses / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Skin Diseases / microbiology
  • [MeSH-minor] Adult. Hematopoietic Stem Cell Transplantation. Humans. Male. Pyrimidines / therapeutic use. Transplantation, Homologous. Treatment Outcome. Triazoles / therapeutic use. Voriconazole

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18203025.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Pyrimidines; 0 / Triazoles; JFU09I87TR / Voriconazole
  •  go-up   go-down


63. Kidas E, Möricke A, Beier R, Welte K, Schrappe M, Stanulla M, Grigull L: Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study. Int J Hematol; 2009 Jun;89(5):584-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic polymorphisms of the lymphotoxin alpha gene are associated with increased risk for lethal infections during induction therapy for childhood acute leukemia: a case-control study.
  • Specific mutations of the TNF-alpha (TNF-alpha) and Lymphotoxin-alpha (LT-alpha) genes are correlated to the outcome of patients during serious infections.
  • This study aimed at correlating these polymorphisms to lethal infections during childhood acute lymphoblastic leukemia (ALL).
  • Genomic DNA was isolated from blood smears and specific fragments including the polymorphic site of each gene were amplified.
  • These results support a role of specific genetic polymorphisms on lethal infections during induction chemotherapy of ALL treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Infection / genetics. Polymorphism, Genetic. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Infect Dis. 1992 Apr;14(4):949-51 [1576293.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1222-8 [10666194.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):50-8 [16173962.001]
  • [Cites] Blood. 2008 May 1;111(9):4477-89 [18285545.001]
  • [Cites] Mycoses. 2003 Dec;46(11-12):441-6 [14641615.001]
  • [Cites] Am J Med. 2001 Apr 15;110(6):486-8 [11331061.001]
  • [Cites] Hum Mol Genet. 1992 Aug;1(5):353 [1363876.001]
  • [Cites] Crit Care Med. 2000 Aug;28(8):2733-6 [10966243.001]
  • [Cites] Crit Care Med. 1996 Mar;24(3):381-4 [8625623.001]
  • [Cites] J Exp Med. 1991 Jan 1;173(1):209-19 [1670638.001]
  • [Cites] J Infect Dis. 1996 Oct;174(4):878-80 [8843235.001]
  • [Cites] JAMA. 1999 Aug 11;282(6):561-8 [10450718.001]
  • [Cites] Shock. 2000 Sep;14(3):307-10; discussion 310-3 [11028548.001]
  • [Cites] Curr Opin Hematol. 1998 Jan;5(1):26-32 [9515199.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Jun;163(7):1599-604 [11401880.001]
  • [Cites] Pediatr Crit Care Med. 2005 Jan;6(1):2-8 [15636651.001]
  • [Cites] N Engl J Med. 1996 Jun 27;334(26):1717-25 [8637518.001]
  • [Cites] J Inflamm. 1995;45(1):1-12 [7583349.001]
  • [Cites] Eur Cytokine Netw. 1995 Mar-Apr;6(2):83-96 [7578992.001]
  • [Cites] Support Care Cancer. 1996 May;4(3):207-12 [8739654.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):580-8 [9401070.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2357-62 [9649158.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):107-12 [9136948.001]
  • [Cites] Pediatr Crit Care Med. 2002 Oct;3(4):341-4 [12780951.001]
  • [Cites] Eur J Haematol. 2006 Jun;76(6):481-7 [16494622.001]
  • [Cites] Infection. 2000 Mar-Apr;28(2):92-6 [10782394.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 19353239.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Lymphotoxin-alpha
  •  go-up   go-down


64. Savage E, Riordan AO, Hughes M: Quality of life in children with acute lymphoblastic leukaemia: a systematic review. Eur J Oncol Nurs; 2009 Feb;13(1):36-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality of life in children with acute lymphoblastic leukaemia: a systematic review.
  • Quality of life (QOL) in children with acute lymphoblastic leukaemia (ALL) is now considered an important outcome measure of treatment for this disease.
  • [MeSH-major] Attitude to Health. Nursing Methodology Research / organization & administration. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Psychology, Child. Quality of Life / psychology

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019732.001).
  • [ISSN] 1532-2122
  • [Journal-full-title] European journal of oncology nursing : the official journal of European Oncology Nursing Society
  • [ISO-abbreviation] Eur J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Number-of-references] 29
  •  go-up   go-down


65. Wong WS, Cheng KC, Lau KM, Chan NP, Shing MM, Cheng SH, Chik KW, Li CK, Ng MH: Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases. Leuk Res; 2007 Feb;31(2):235-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
  • We describe a case of coexisting BCR-ABL negative myeloproliferative disorder and precursor T-cell lymphoblastic lymphoma associated with t(8;13) involving FGFR1 at 8p11 in a 14-year-old boy who presented with generalized lymphadenopathy and an abdominal mass.
  • RT-PCR revealed the ZNF198-FGFR1 fusion transcript in both the bone marrow (BM) and lymph node (LN) of the patient at diagnosis.
  • [MeSH-major] Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 8 / genetics. Myeloproliferative Disorders / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Bone Marrow / pathology. Cell Transformation, Neoplastic / genetics. China / epidemiology. Clone Cells. Disease Progression. Genes, T-Cell Receptor gamma / genetics. Hematopoietic Stem Cells / pathology. Humans. Male. Receptor, Fibroblast Growth Factor, Type 1 / genetics. Remission Induction. Syndrome. Translocation, Genetic / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16777224.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  •  go-up   go-down


66. Douer D, Yampolsky H, Cohen LJ, Watkins K, Levine AM, Periclou AP, Avramis VI: Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood; 2007 Apr 1;109(7):2744-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia.
  • We administered a single intravenous dose of pegaspargase (2000 IU/m2) as part of a standard frontline induction regimen to 25 adults with newly diagnosed acute lymphoblastic leukemia (ALL), and obtained serum samples on several time points.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Asparaginase / pharmacology. Polyethylene Glycols / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17132721.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


67. Mishra P, Kumar R, Mahapatra M, Sharma S, Dixit A, Chaterjee T, Choudhry DR, Saxena R, Choudhry VP: Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology; 2006 Oct;11(5):335-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberculosis in acute leukemia: a clinico-hematological profile.
  • We studied 130 consecutive cases of acute leukemia over a 2-year period and identified 9 cases (6.9%) with active tuberculosis (TB).
  • Eight patients with TB had acute myeloid leukemia (AML).
  • Patients with AML were more likely to develop TB as compared to patients with acute lymphoblastic leukemia (ALL) despite the wider use of steroids and radiotherapy in ALL protocols {OR 4.41 (CI 0.53-36.44)}.
  • However it is not a commonly described infection in acute leukemia and a high index of suspicion is warranted especially in areas endemic for TB.
  • [MeSH-major] Leukemia / complications. Tuberculosis / etiology
  • [MeSH-minor] Acute Disease. Adult. Antitubercular Agents / therapeutic use. Female. Humans. Incidence. Leukemia, Myeloid. Male. Neutropenia. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607583.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


68. Cocco C, Canale S, Frasson C, Di Carlo E, Ognio E, Ribatti D, Prigione I, Basso G, Airoldi I: Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood; 2010 Nov 11;116(19):3887-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells.
  • The aim of this study was to investigate the potential direct antitumor activity of IL-23 in pediatric B-acute lymphoblastic leukemia (B-ALL) cells and to unravel the molecular mechanisms involved.
  • Here, we show, for the first time, that IL-23R is up-regulated in primary B-ALL cells, compared with normal early B lymphocytes, and that IL-23 dampens directly tumor growth in vitro and in vivo through the inhibition of tumor cell proliferation and induction of apoptosis.
  • [MeSH-major] Interleukin-23 Subunit p19 / immunology. Interleukin-23 Subunit p19 / pharmacology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Child. Child, Preschool. Female. Gene Expression / drug effects. Genes, bcl-2 / drug effects. Humans. In Vitro Techniques. Infant. Male. Mice. Mice, Inbred NOD. Mice, SCID. MicroRNAs / antagonists & inhibitors. MicroRNAs / genetics. Recombinant Proteins / genetics. Recombinant Proteins / immunology. Recombinant Proteins / pharmacology. Signal Transduction / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20671120.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL23A protein, human; 0 / Interleukin-23 Subunit p19; 0 / MIRN15 microRNA, human; 0 / MicroRNAs; 0 / Recombinant Proteins
  •  go-up   go-down


69. El-Sharnouby JA, Abou El-Enein AM, El Ghannam DM, El-Shanshory MR, Hagag AA, Yahia S, Elashry R: Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia. J Oncol Pharm Pract; 2010 Sep;16(3):179-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of lung resistance protein and multidrug resistance-related protein (MRP1) in pediatric acute lymphoblastic leukemia.
  • The prognostic value that lung resistance protein (LRP) and multidrug resistance-related protein 1 (MRP1) have in the setting of pediatric acute lymphoblastic leukemia (ALL) is controversial.
  • Thus, diagnosis appears to provide prognostic information for pediatric ALL.
  • [MeSH-major] Multidrug Resistance-Associated Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / biosynthesis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19969624.001).
  • [ISSN] 1477-092X
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / RNA, Messenger; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1
  •  go-up   go-down


70. Dokmanović L, Janić D, Krstovski N, Zukić B, Tosić N, Pavlović S: [Importance of genotyping of thiopurine S-methyltransferase in children with acute lymphoblastic leukaemia during maintenance therapy]. Srp Arh Celok Lek; 2008 Nov-Dec;136(11-12):609-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of genotyping of thiopurine S-methyltransferase in children with acute lymphoblastic leukaemia during maintenance therapy].
  • INTRODUCTION: Thiopurine S-methyltransferase (TPMT) is an enzyme that catalyses the inactivation of mercaptopurine (MP) which is widely used in the treatment of acute lymphoblastic leukaemia (ALL) of childhood.
  • [MeSH-major] 6-Mercaptopurine / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Methyltransferases / genetics. Mutation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19177822.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase
  •  go-up   go-down


71. Blair CK, Roesler M, Xie Y, Gamis AS, Olshan AF, Heerema NA, Robison LL, Ross JA, Children's Oncology Group (COG): Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study. Paediatr Perinat Epidemiol; 2008 May;22(3):288-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study.
  • Because children with DS have a 50-fold increased risk of developing acute leukaemia during the first 5 years of life, we explored the relation between child vitamin and herbal supplement use and the risk of leukaemia in a case-control study.
  • During the period 1997-2002, we enrolled 158 children with DS aged 0-18 years that were diagnosed with acute lymphoblastic leukaemia (ALL) (n = 97) or acute myeloid leukaemia (AML) (n = 61) at participating Children's Oncology Group institutions.
  • We enrolled 173 DS children without leukaemia (controls), selected from the cases' primary care clinic and frequency-matched on age.
  • Despite being the largest study of DS-leukaemia, our sample size was small, resulting in imprecise effect estimates.
  • Future research should include larger sample sizes as well as a full assessment of diet including vitamin supplementation to adequately examine the relation between nutritional status and childhood leukaemia.

  • MedlinePlus Health Information. consumer health - Dietary Supplements.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatrics. 1997 Nov;100(5):E4 [9346998.001]
  • [Cites] Blood. 1998 Jan 15;91(2):608-15 [9427716.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1866-72 [15520821.001]
  • [Cites] Pediatr Blood Cancer. 2005 Jan;44(1):40-4 [15390312.001]
  • [Cites] Adv Data. 2004 Nov 9;(349):1-7 [15586828.001]
  • [Cites] J Am Diet Assoc. 2005 May;105(5):763-72; quiz 773-4 [15883554.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):405-10 [15952191.001]
  • [Cites] Proc Nutr Soc. 2005 Nov;64(4):543-53 [16313697.001]
  • [Cites] J Am Diet Assoc. 2006 Jan;106(1 Suppl 1):S52-65 [16376630.001]
  • [Cites] J Pediatr Health Care. 2006 Jan-Feb;20(1):47-54 [16399479.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3339-44 [16492768.001]
  • [Cites] Mutat Res. 2001 Apr 18;475(1-2):7-20 [11295149.001]
  • [Cites] Ann N Y Acad Sci. 1999;889:87-106 [10668486.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] J Am Diet Assoc. 2000 Mar;100(3):371-5 [10719417.001]
  • [Cites] Arch Fam Med. 2000 Mar;9(3):258-62 [10728113.001]
  • [Cites] Dev Med Child Neurol. 2000 Mar;42(3):207-13 [10755461.001]
  • [Cites] Lancet. 2001 Dec 8;358(9297):1935-40 [11747917.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1786-94 [12365028.001]
  • [Cites] Br J Nutr. 2002 Nov;88 Suppl 2:S165-77 [12495459.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1339-45 [12599243.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):930-8 [12648061.001]
  • [Cites] Lancet. 2003 Apr 12;361(9365):1281-9 [12699967.001]
  • [Cites] Blood. 2004 Jan 15;103(2):399-406 [14512321.001]
  • [Cites] Int J Vitam Nutr Res. 1978;48(2):188-216 [151083.001]
  • [Cites] Endocrinologie. 1988 Apr-Jun;26(2):113-7 [2970667.001]
  • [Cites] Clin Immunol Immunopathol. 1991 Feb;58(2):207-16 [1824686.001]
  • [Cites] Int J Neurosci. 1992 Jul-Aug;65(1-4):259-68 [1341688.001]
  • [Cites] N Engl J Med. 1994 Apr 14;330(15):1029-35 [8127329.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):141-8 [8167261.001]
  • [Cites] Cancer Causes Control. 1994 Mar;5(2):195-202 [8167267.001]
  • [Cites] N Engl J Med. 1996 May 2;334(18):1150-5 [8602180.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):201-7 [8630931.001]
  • [Cites] Cancer Causes Control. 1997 Sep;8(5):786-802 [9328202.001]
  • [Cites] Am J Epidemiol. 2004 Dec 1;160(11):1098-107 [15561989.001]
  • (PMID = 18426524.001).
  • [ISSN] 1365-3016
  • [Journal-full-title] Paediatric and perinatal epidemiology
  • [ISO-abbreviation] Paediatr Perinat Epidemiol
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / R01 CA075169; United States / NCI NIH HHS / CA / R01 CA75169; United States / NCI NIH HHS / CA / U10 CA098543; United States / NIEHS NIH HHS / ES / P30ES10126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vitamins
  • [Other-IDs] NLM/ NIHMS378452; NLM/ PMC3365502
  •  go-up   go-down


72. Santos FP, Rodrigues M, Mac-Donald Bley do Nascimento C, Kerbauy FR, Ribeiro AA, Mauro Kutner J, Hamerschlak N: Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib. Cytotherapy; 2010;12(1):113-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced. Protein Kinase Inhibitors / adverse effects. Pyrimidines / adverse effects. Thiazoles / adverse effects
  • [MeSH-minor] Aged. Benzamides. Blast Crisis / chemically induced. Blast Crisis / immunology. Blast Crisis / physiopathology. Dasatinib. Hematopoietic Stem Cell Transplantation. Humans. Iatrogenic Disease / prevention & control. Imatinib Mesylate. Immunosuppressive Agents / therapeutic use. Male. Middle Aged. Piperazines / pharmacology. Piperazines / therapeutic use. Prednisone / therapeutic use. Remission Induction / methods. Treatment Outcome


73. McGrath P, Rawson-Huff N: Corticosteroids during continuation therapy for acute lymphoblastic leukemia: the psycho-social impact. Issues Compr Pediatr Nurs; 2010;33(1):5-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corticosteroids during continuation therapy for acute lymphoblastic leukemia: the psycho-social impact.
  • This article presents the findings of qualitative research exploring the psycho-social effects of corticosteroid use in pediatric hematology patients during continuation therapy for Acute Lymphoblastic Leukemia (ALL).
  • The findings are from a 5-year longitudinal study that documented the experience of treatment for childhood leukemia and related disorders from the perspective of the child patient and their family from the point of diagnosis to 1 year post-treatment.
  • [MeSH-major] Child Behavior / drug effects. Glucocorticoids / adverse effects. Health Knowledge, Attitudes, Practice. Parent-Child Relations. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20121577.001).
  • [ISSN] 1521-043X
  • [Journal-full-title] Issues in comprehensive pediatric nursing
  • [ISO-abbreviation] Issues Compr Pediatr Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


74. Naithani R, Rai S, Choudhry VP: Septic arthritis of hip in a neutropenic child caused by Salmonella typhi. J Pediatr Hematol Oncol; 2008 Feb;30(2):182-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 5-year-old male child was undergoing chemotherapy for pre-B acute lymphoblastic leukemia.
  • [MeSH-major] Arthritis, Infectious / etiology. Hip Joint. Neutropenia / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Typhoid Fever / complications

  • Genetic Alliance. consumer health - Arthritis.
  • MedlinePlus Health Information. consumer health - Infectious Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376276.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


75. Kummoona R, Maky A: Apoptotic changes of Middle East jaw lymphoma. J Craniofac Surg; 2006 Mar;17(2):231-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ground section shows lymphoblastic lymphoma, darkly-stained of ribonucleic acid, also apoptotic changes seen in some of the cells.
  • Electron microscopy showed high mitotic figures, lymphoblast transformed to plasma cell, high nucleocytoplasmic ratio, some cells showed double nuclei, some nuclei are crested in shape or convoluted, degenerative changes seen in some of the cells, chromatin clumps near the nuclear membrane, mitochondria showing homogenous and degenerative changes, virus like particles seen in this nucleus and cytoplasm.
  • The presence of low-level of apoptosis is a poor prognostic feature of jaw lymphoma due to homogeneity and degenerative changes of the mitochondria and disruption of the cell surface.
  • [MeSH-major] Apoptosis. Jaw Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16633167.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Zuckerman T, Rowe JM: Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia. Curr Opin Hematol; 2009 Nov;16(6):453-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia.
  • PURPOSE OF REVIEW: The long-term survival for patients with adult acute lymphoblastic leukemia (ALL) has not significantly changed over the past two decades and, as opposed to pediatric ALL, it is less than 40% despite high initial complete remission rate.
  • Limited data on the use of alternative donor transplantation as well as reduced intensity protocols are now available for consideration in specific groups of patients.
  • SUMMARY: Data suggest that the best antileukemic treatment should be applied in first remission and type of treatment should be based on individualized risk stratification, while incorporating recent information on alternative donors and reduced intensity approaches to transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma


77. Alderton LE, Spector LG, Blair CK, Roesler M, Olshan AF, Robison LL, Ross JA: Child and maternal household chemical exposure and the risk of acute leukemia in children with Down's syndrome: a report from the Children's Oncology Group. Am J Epidemiol; 2006 Aug 1;164(3):212-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Child and maternal household chemical exposure and the risk of acute leukemia in children with Down's syndrome: a report from the Children's Oncology Group.
  • Compared with the general pediatric population, children with Down's syndrome have a much higher risk of acute leukemia.
  • This case-control study was designed to explore potential risk factors for acute lymphoblastic leukemia and acute myeloid leukemia in children with Down's syndrome living in the United States or Canada.
  • Mothers of 158 children with Down's syndrome and acute leukemia (97 acute lymphoblastic leukemia, 61 acute myeloid leukemia) diagnosed between January 1997 and October 2002 and mothers of 173 children with Down's syndrome but without leukemia were interviewed by telephone.
  • Positive associations were found between acute lymphoblastic leukemia and maternal exposure to professional pest exterminations (odds ratio = 2.25, 95% confidence interval: 1.13, 4.49), to any pesticide (odds ratio = 2.18, 95% confidence interval: 1.08, 4.39), and to any chemical (odds ratio = 2.72, 95% confidence interval: 1.17, 6.35).
  • Most of the associations with acute myeloid leukemia were nonsignificant, and odds ratios were generally near or below 1.0.
  • This exploratory study suggests that household chemical exposure may play a role in the development of acute lymphoblastic leukemia in children with Down's syndrome.

  • Genetic Alliance. consumer health - CHILD Syndrome.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • MedlinePlus Health Information. consumer health - Household Products.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16760223.001).
  • [ISSN] 0002-9262
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA075169; United States / NIEHS NIH HHS / ES / P30ES10126; United States / NCI NIH HHS / CA / R01-CA75169
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pesticides; 0 / Petroleum
  •  go-up   go-down


78. Steinemann D, Cario G, Stanulla M, Karawajew L, Tauscher M, Weigmann A, Göhring G, Ludwig WD, Harbott J, Radlwimmer B, Bartram C, Lichter P, Schrappe M, Schlegelberger B: Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease. Genes Chromosomes Cancer; 2008 Jun;47(6):471-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Copy number alterations in childhood acute lymphoblastic leukemia and their association with minimal residual disease.
  • In vivo response to initial therapy, as assessed by determination of minimal residual disease (MRD) after 5 and 12 weeks of treatment, has evolved as a strong prognostic factor in children with acute lymphoblastic leukemia (ALL) treated according to the BFM regime.
  • [MeSH-major] Gene Dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


79. Feltbower RG, Manda SO, Gilthorpe MS, Greaves MF, Parslow RC, Kinsey SE, Bodansky HJ, McKinney PA: Detecting small-area similarities in the epidemiology of childhood acute lymphoblastic leukemia and diabetes mellitus, type 1: a Bayesian approach. Am J Epidemiol; 2005 Jun 15;161(12):1168-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detecting small-area similarities in the epidemiology of childhood acute lymphoblastic leukemia and diabetes mellitus, type 1: a Bayesian approach.
  • Childhood acute lymphoblastic leukemia and diabetes mellitus, type 1, have common epidemiologic and etiologic features, including correlated international incidence and associations with infections.
  • Details of 299 children (0-14 years) with acute lymphoblastic leukemia and 1,551 children with diabetes diagnosed between 1986 and 1998 were extracted from two registers in Yorkshire, United Kingdom.
  • The links between diabetes and acute lymphoblastic leukemia observed for large regions are weaker for small areas.
  • [MeSH-major] Diabetes Mellitus, Type 1 / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology


80. Bagatell R, Hainstock M, Lowe MC, Barber BJ, Samson RA: The perfect storm: Torsades de Pointes in a child with leukemia. Pediatr Blood Cancer; 2007 Dec;49(7):996-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The perfect storm: Torsades de Pointes in a child with leukemia.
  • Torsades de Pointes (TdP) is a life-threatening ventricular arrhythmia that can be associated with metabolic abnormalities, exposure to arrhythmogenic medications, and congenital long-QT syndrome.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Torsades de Pointes / complications
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / adverse effects. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cardiopulmonary Resuscitation. Ecthyma / diagnosis. Ecthyma / drug therapy. Electrocardiography. Electrolytes / administration & dosage. Electrolytes / blood. Female. Follow-Up Studies. Heart Arrest / etiology. Heart Arrest / therapy. Humans. Kidney Diseases / chemically induced. Kidney Diseases / therapy. Long QT Syndrome / complications. Long QT Syndrome / diagnosis. Long QT Syndrome / drug therapy. Remission Induction. Treatment Outcome. Ventricular Premature Complexes / complications. Ventricular Premature Complexes / diagnosis. Ventricular Premature Complexes / drug therapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc
  • (PMID = 16333840.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Electrolytes
  •  go-up   go-down


81. Menon J, Mathews L, Purushothaman KK: Treating leukemia in a resource poor setting. Indian Pediatr; 2008 May;45(5):410-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating leukemia in a resource poor setting.
  • Acute lymphatic leukemia (ALL) is the commonest childhood malignancy in India; most patients have no access to specialized health care.
  • The case records of 79 patients with acute lymphatic leukemia, treated at a Government Medical College in Kerala over 15 years were analyzed.
  • [MeSH-major] Health Care Rationing. Health Services Accessibility. Precursor Cell Lymphoblastic Leukemia-Lymphoma / economics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18515933.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


82. Delgado MD, León J: Myc roles in hematopoiesis and leukemia. Genes Cancer; 2010 Jun;1(6):605-16
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myc roles in hematopoiesis and leukemia.
  • Hematopoiesis is a process capable of generating millions of cells every second, as distributed in many cell types.
  • The process is regulated by a number of transcription factors that regulate the differentiation along the distinct lineages and dictate the genetic program that defines each mature phenotype.
  • When transgenic mice overexpress c-Myc or N-Myc in mature cells from the lymphoid or myeloid lineages, the result is lymphoma or leukemia.
  • In agreement, enforced expression of c-Myc blocks the differentiation in several leukemia-derived cell lines capable of differentiating in culture.
  • Not surprising, MYC deregulation is recurrently found in many types of human lymphoma and leukemia.
  • Whereas MYC is deregulated by translocation in Burkitt lymphoma and, less frequently, other types of lymphoma, MYC is frequently overexpressed in acute lymphoblastic and myeloid leukemia, through mechanisms unrelated to chromosomal translocation, and is often associated with disease progression.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2010 Mar 1;116(5):1165-76 [20101737.001]
  • [Cites] Cancer Genet Cytogenet. 2010 Feb;197(1):75-80 [20113841.001]
  • [Cites] Blood. 2010 Apr 8;115(14):2845-51 [20124220.001]
  • [Cites] Haematologica. 2010 Apr;95(4):597-603 [20378577.001]
  • [Cites] Blood. 1991 Jul 1;78(1):180-91 [2070052.001]
  • [Cites] Crit Rev Oncog. 1990;2(1):75-95 [2091750.001]
  • [Cites] Adv Cancer Res. 1990;55:133-270 [2166998.001]
  • [Cites] J Virol. 1979 Aug;31(2):514-21 [225569.001]
  • [Cites] Cell. 1986 Oct 10;47(1):11-8 [3093082.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Aug;85(16):6047-51 [3261863.001]
  • [Cites] Nature. 1986 Apr 24-30;320(6064):760-3 [3458027.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Mar;83(5):1495-8 [3513178.001]
  • [Cites] Nature. 1986 Aug 21-27;322(6081):748-50 [3528861.001]
  • [Cites] Nature. 1986 Aug 28-Sep 3;322(6082):848-50 [3528863.001]
  • [Cites] Nature. 1985 Dec 12-18;318(6046):533-8 [3906410.001]
  • [Cites] Annu Rev Genet. 1984;18:553-612 [6397126.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10302-6 [7479772.001]
  • [Cites] J Exp Med. 1995 May 1;181(5):1603-13 [7722440.001]
  • [Cites] Oncogene. 1995 Apr 20;10(8):1659-65 [7731722.001]
  • [Cites] Science. 1994 Apr 15;264(5157):424-6 [8153630.001]
  • [Cites] Genes Dev. 2002 Oct 1;16(19):2530-43 [12368264.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7137-46 [12370803.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1220-35 [12393483.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1950-5 [12406913.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14925-30 [12417757.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):351-60 [12545156.001]
  • [Cites] Annu Rev Immunol. 2003;21:759-806 [12615892.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):178-82 [15287031.001]
  • [Cites] Am J Hematol. 2004 Sep;77(1):55-61 [15307107.001]
  • [Cites] Genes Dev. 2004 Nov 15;18(22):2747-63 [15545632.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):172-8 [15654333.001]
  • [Cites] Annu Rev Med. 2005;56:509-38 [15660525.001]
  • [Cites] Oncogene. 2005 May 19;24(22):3544-53 [15688022.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1306-15 [15735016.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(6):2395-405 [15743832.001]
  • [Cites] Annu Rev Immunol. 2005;23:601-49 [15771582.001]
  • [Cites] Blood. 2005 Aug 1;106(3):871-8 [15840692.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2452-61 [15972450.001]
  • [Cites] Nature. 2005 Aug 11;436(7052):807-11 [16094360.001]
  • [Cites] Curr Top Microbiol Immunol. 2005;294:109-33 [16329193.001]
  • [Cites] Hum Mol Genet. 2006 Mar 15;15(6):933-42 [16452126.001]
  • [Cites] Blood. 2006 Jul 15;108(2):653-61 [16537801.001]
  • [Cites] Nat Immunol. 2006 Apr;7(4):333-7 [16550195.001]
  • [Cites] Nat Rev Cancer. 2006 May;6(5):347-59 [16612405.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2669-77 [16788099.001]
  • [Cites] DNA Repair (Amst). 2006 Sep 8;5(9-10):1213-24 [16815105.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1572-81 [16855632.001]
  • [Cites] Mayo Clin Proc. 2006 Aug;81(8):1105-29 [16901035.001]
  • [Cites] Leuk Lymphoma. 1998 Jul;30(3-4):293-306 [9713961.001]
  • [Cites] Oncogene. 1998 Oct 22;17(16):2073-85 [9798678.001]
  • [Cites] EMBO J. 1999 Feb 1;18(3):717-26 [9927431.001]
  • [Cites] Leuk Res. 1997 Jun;21(6):479-89 [9279359.001]
  • [Cites] Oncogene Res. 1991;6(1):21-32 [1997946.001]
  • [Cites] Mol Cell Biol. 1989 Mar;9(3):1263-70 [2725497.001]
  • [Cites] J Immunol. 1989 Aug 1;143(3):1032-9 [2787345.001]
  • [Cites] EMBO J. 1988 Sep;7(9):2787-94 [3053165.001]
  • [Cites] Mol Cell Biol. 1988 Feb;8(2):963-73 [3280975.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Apr;85(8):2638-42 [3357885.001]
  • [Cites] Cancer Res. 1986 Oct;46(10):5162-6 [3756869.001]
  • [Cites] Leukemia. 1993 Nov;7(11):1824-33 [8231250.001]
  • [Cites] Oncogene. 1995 Dec 7;11(11):2439-44 [8570196.001]
  • [Cites] Immunity. 2007 Jun;26(6):726-40 [17582345.001]
  • [Cites] Exp Hematol. 2007 Sep;35(9):1333-43 [17637497.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Nov;46(11):1039-50 [17696194.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):8-20 [17910043.001]
  • [Cites] Genes Dev. 2008 Apr 15;22(8):986-91 [18367647.001]
  • [Cites] Exp Hematol. 2008 Jul;36(7):871-85 [18375040.001]
  • [Cites] Br J Haematol. 2008 Jul;142(1):36-44 [18477041.001]
  • [Cites] Nature. 2008 May 15;453(7193):306-13 [18480811.001]
  • [Cites] Development. 2008 Aug;135(14):2455-65 [18550708.001]
  • [Cites] Development. 2008 Aug;135(14):2467-77 [18550710.001]
  • [Cites] PLoS Biol. 2008 Jun 24;6(6):e152 [18578569.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5314-7 [18765521.001]
  • [Cites] Blood. 2009 Feb 19;113(8):1619-30 [18827185.001]
  • [Cites] Curr Opin Genet Dev. 2008 Dec;18(6):530-5 [18838119.001]
  • [Cites] Mol Cell Biol. 2008 Dec;28(24):7286-95 [18838534.001]
  • [Cites] J Immunol. 2008 Dec 1;181(11):7537-49 [19017943.001]
  • [Cites] Cell Stem Cell. 2008 Dec 4;3(6):611-24 [19041778.001]
  • [Cites] Cancer Cell. 2008 Dec 9;14(6):447-57 [19061836.001]
  • [Cites] Oncogene. 2009 Mar 5;28(9):1274-9 [19137012.001]
  • [Cites] Cell Cycle. 2009 Apr 15;8(8):1148-57 [19282668.001]
  • [Cites] Hematol Oncol. 2010 Jun;28(2):62-7 [20014148.001]
  • [Cites] Nat Immunol. 2010 Mar;11(3):207-15 [20081848.001]
  • [Cites] Leukemia. 2003 Apr;17(4):813-5 [12682646.001]
  • [Cites] Oncogene. 2003 Jun 19;22(25):3952-63 [12813469.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):384-92 [15023043.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2890-904 [15024077.001]
  • [Cites] J Biol Chem. 2004 Jun 11;279(24):24986-93 [15067010.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Leuk Res. 2004 Jul;28(7):743-53 [15158096.001]
  • [Cites] Blood. 2004 Dec 1;104(12):3679-87 [15226186.001]
  • [Cites] Cell. 1992 Sep 18;70(6):901-10 [1525828.001]
  • [Cites] J Immunol. 2009 Apr 15;182(8):4641-8 [19342639.001]
  • [Cites] Blood. 2009 Sep 3;114(10):2097-106 [19372257.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):624-36 [19396865.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 May 26;106(21):8641-6 [19423665.001]
  • [Cites] Blood. 2009 Sep 3;114(10):2087-96 [19542301.001]
  • [Cites] Cancer Genet Cytogenet. 2009 Jul 15;192(2):96-8 [19596264.001]
  • [Cites] IUBMB Life. 2009 Aug;61(8):800-30 [19621348.001]
  • [Cites] Blood. 2009 Dec 24;114(27):5499-511 [19855079.001]
  • [Cites] Oncogene. 2010 Feb 11;29(6):888-97 [19881537.001]
  • [Cites] Semin Cancer Biol. 2006 Aug;16(4):318-30 [16934487.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Leukemia. 2007 Mar;21(3):494-504 [17252012.001]
  • [Cites] Cell Cycle. 2007 Apr 15;6(8):927-30 [17404512.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):441-53 [17522713.001]
  • [Cites] Immunity. 2007 Jun;26(6):715-25 [17582344.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6687-96 [17934478.001]
  • [Cites] Oncogene. 2007 Oct 15;26(47):6777-94 [17934485.001]
  • [Cites] J Cell Biol. 2007 Nov 19;179(4):717-31 [17998397.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10677-85 [18006809.001]
  • [Cites] Ann Hematol. 2008 Apr;87(4):263-8 [18084761.001]
  • [Cites] Eur J Immunol. 2008 Feb;38(2):342-9 [18196519.001]
  • [Cites] Cell. 2008 Feb 22;132(4):631-44 [18295580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):228-33 [10618400.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2104-10 [10706881.001]
  • [Cites] Mol Cell Biol. 2000 Apr;20(7):2423-35 [10713166.001]
  • [Cites] Genes Dev. 2000 Jun 1;14(11):1390-9 [10837031.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1314-5 [10914558.001]
  • [Cites] Immunity. 2001 Jan;14(1):45-55 [11163229.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1178-86 [11221849.001]
  • [Cites] Genes Dev. 1993 Apr;7(4):671-82 [8458579.001]
  • [Cites] J Biol Chem. 1996 May 24;271(21):12681-6 [8647882.001]
  • [Cites] Nature. 1996 Jun 27;381(6585):751-8 [8657279.001]
  • [Cites] J Biol Chem. 1996 Sep 20;271(38):22976-82 [8798484.001]
  • [Cites] Oncogene. 1997 Mar 20;14(11):1315-27 [9178892.001]
  • [Cites] Oncogene. 1997 Jun 12;14(23):2835-43 [9190900.001]
  • [Cites] Mol Cell. 1999 Aug;4(2):199-207 [10488335.001]
  • [Cites] Cell Growth Differ. 1999 Sep;10(9):639-54 [10511314.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Cancer Res. 1999 Nov 1;59(21):5625-8 [10554044.001]
  • [Cites] Mol Cancer Ther. 2003 Sep;2(9):893-900 [14555708.001]
  • [Cites] Haematologica. 2004 Feb;89(2):241-3 [15003904.001]
  • [Cites] Oncogene. 1992 Sep;7(9):1827-36 [1501891.001]
  • [Cites] Mol Cell Biol. 1992 Apr;12(4):1578-84 [1549113.001]
  • [Cites] APMIS. 2006 Jun;114(6):436-9 [16856965.001]
  • [Cites] Exp Hematol. 2006 Nov;34(11):1480-9 [17046567.001]
  • [Cites] Blood. 1991 Mar 1;77(5):1025-32 [1899807.001]
  • [Cites] Nat Immunol. 2001 Apr;2(4):307-15 [11276201.001]
  • [Cites] Mol Cell Biol. 2001 Jun;21(11):3789-806 [11340171.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5595-610 [11607812.001]
  • [Cites] Blood. 2001 Nov 15;98(10):3082-6 [11698294.001]
  • [Cites] Nature. 2001 Dec 13;414(6865):768-73 [11742404.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1922-7 [11896625.001]
  • [Cites] Acta Haematol. 2002;107(2):76-94 [11919388.001]
  • [Cites] Haematologica. 2002 Jun;87(6):569-77 [12031912.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):289-98 [12086865.001]
  • (PMID = 21779460.001).
  • [ISSN] 1947-6027
  • [Journal-full-title] Genes & cancer
  • [ISO-abbreviation] Genes Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3092227
  • [Keywords] NOTNLM ; Myc / differentiation / hematopoietic stem cells / leukemia
  •  go-up   go-down


83. Janiszewska H, Styczynski J, Kolodziej B, Wysocki M, Haus O: Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia. Ann Hematol; 2009 Dec;88(12):1193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the MDR1 gene expression after short-term ex vivo therapy with prednisolone have prognostic impact in childhood acute lymphoblastic leukemia.
  • Multidrug resistance 1 (MDR1) gene expression determined by real-time polymerase chain reaction and results of rhodamine assay were analyzed at diagnosis and after 3 days of ex vivo therapy with prednisolone in 36 pediatric patients with acute lymphoblastic leukemia (ALL).
  • Only 62% patients with de novo ALL had significant decrease of MDR1 expression.
  • In this study, we have shown that changes in the expression of MDR1 gene after short-term incubation of lymphoblasts with prednisolone may have prognostic value in pediatric de novo ALL patients.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Gene Expression Regulation, Neoplastic. P-Glycoprotein. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352661.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Antineoplastic Agents, Hormonal; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


84. Mansour MR, Sulis ML, Duke V, Foroni L, Jenkinson S, Koo K, Allen CG, Gale RE, Buck G, Richards S, Paietta E, Rowe JM, Tallman MS, Goldstone AH, Ferrando AA, Linch DC: Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. J Clin Oncol; 2009 Sep 10;27(26):4352-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
  • PURPOSE: Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic leukemia (T-ALL) and, in pediatric disease, predicts for favorable outcome.
  • We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol.
  • RESULTS: NOTCH1 and FBXW7 mutations were common (60% and 18%, respectively) and were not associated with age or WBC count.
  • Patients wild type (WT) for both markers trended toward poorer event-free survival (EFS; MUT v WT, 51% v 27%, P = .10; hazard ratio, 0.6).
  • [MeSH-major] Cell Cycle Proteins / genetics. F-Box Proteins / genetics. Mutation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Receptor, Notch1 / genetics. Ubiquitin-Protein Ligases / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3043-9 [16707600.001]
  • [Cites] Genes Dev. 2006 Aug 1;20(15):2096-109 [16847353.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1151-7 [16614245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18261-6 [17114293.001]
  • [Cites] Nat Med. 2007 Jan;13(1):70-7 [17173050.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5611-6 [17575125.001]
  • [Cites] Blood. 2007 Jul 1;110(1):278-86 [17363738.001]
  • [Cites] Nature. 2007 Jun 21;447(7147):966-71 [17515920.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1262-70 [17456725.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1825-35 [17646408.001]
  • [Cites] J Exp Med. 2007 Aug 6;204(8):1813-24 [17646409.001]
  • [Cites] Nat Med. 2007 Oct;13(10):1203-10 [17873882.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6964-9 [18056171.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Leuk Res. 2008 Nov;32(11):1751-5 [18485478.001]
  • [Cites] Blood. 2008 Aug 1;112(3):733-40 [18411416.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4386-93 [12036866.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1126-34 [12414341.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2149-56 [14576730.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • (PMID = 19635999.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00002514
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United States / NCI NIH HHS / CA / R01 CA129382; United Kingdom / Medical Research Council / / ; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01CA129382; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1; EC 2.3.2.27 / Ubiquitin-Protein Ligases; EC 6.3.2.19 / FBXW7 protein, human
  • [Other-IDs] NLM/ PMC2744275
  •  go-up   go-down


85. Tartaglia M, Gelb BD: Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet; 2005;6:45-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Noonan syndrome is a pleiomorphic autosomal dominant disorder with short stature, facial dysmorphia, webbed neck, and heart defects.
  • In the past decade, progress has been made in elucidating the pathogenesis of this disorder using a positional cloning approach.
  • Noonan syndrome is now known to be a genetically heterogeneous disorder with nearly one half of cases caused by gain-of-function mutations in PTPN11, the gene encoding the protein tyrosine phosphatase SHP-2.
  • Similar germ line mutations cause two related genetic disorders, Noonan-like disorder with multiple giant cell lesion syndrome and LEOPARD syndrome, and somatic PTPN11 mutations can underlie certain pediatric hematopoietic malignancies, including juvenile myelomonocytic, acute lymphoblastic, and acute myelogenous leukemias.
  • [MeSH-minor] Animals. Female. Genetic Linkage. Genotype. History, 19th Century. History, 20th Century. Humans. Intracellular Signaling Peptides and Proteins / chemistry. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / physiology. Leukemia / genetics. Male. Mice. Models, Molecular. Mutation. Paternal Age. Phenotype. Protein Tyrosine Phosphatase, Non-Receptor Type 11. Protein Tyrosine Phosphatases / chemistry. Protein Tyrosine Phosphatases / genetics. Protein Tyrosine Phosphatases / physiology

  • Genetic Alliance. consumer health - Noonan Syndrome.
  • Genetics Home Reference. consumer health - PTPN11 gene.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16124853.001).
  • [ISSN] 1527-8204
  • [Journal-full-title] Annual review of genomics and human genetics
  • [ISO-abbreviation] Annu Rev Genomics Hum Genet
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD01294; United States / NHLBI NIH HHS / HL / HL074728; United States / NHLBI NIH HHS / HL / HL71207
  • [Publication-type] Historical Article; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Ptpn11 protein, mouse
  • [Number-of-references] 100
  •  go-up   go-down


86. de Andrade CF, Bigni R, Pombo-de-Oliveira MS, Alves G, Pereira DA: CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia. J Enzyme Inhib Med Chem; 2009 Jun;24(3):708-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD26/DPPIV cell membrane expression and DPPIV activity in plasma of patients with acute leukemia.
  • In this study, we analyzed the CD26 antigen cell membrane expression by flow cytometry and the DPPIV activity in plasma of patients of acute leukemia.
  • The results showed that the plasma DPPIV activity is significantly higher in leukemia patients and could be 100% inhibited by Januvia (Merck Sharp & Dohme) a selective DPPIV inhibitor.
  • Although CD26 expression on immune cells were not leukemia-dependent the analysis of the correlation between CD26 expression and the DPPIV plasma activity were statistically significant (p < 0.01) in acute lymphoid leukemia (B-ALL and T-ALL).
  • [MeSH-major] Cell Membrane / metabolism. Dipeptidyl Peptidase 4 / blood. Dipeptidyl Peptidase 4 / metabolism. Gene Expression Regulation, Neoplastic. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. SITAGLIPTIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469710.001).
  • [ISSN] 1475-6374
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dipeptidyl-Peptidase IV Inhibitors; 0 / Pyrazines; 0 / Triazoles; EC 3.4.14.5 / DPP4 protein, human; EC 3.4.14.5 / Dipeptidyl Peptidase 4; TS63EW8X6F / Sitagliptin Phosphate
  •  go-up   go-down


87. Eun S, Jeon YK, Jang JJ: Hepatocellular carcinoma with immature T-cell (T-lymphoblastic) proliferation. J Korean Med Sci; 2010 Feb;25(2):309-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma with immature T-cell (T-lymphoblastic) proliferation.
  • Indolent T-lymphoblastic proliferation has been rarely reported in the upper aerodigestive tract.
  • We present an unusual type of tumor infiltrating lymphocytes in a case with hepatocellular carcinoma, presumed to be a T-lymphoblastic proliferation.
  • The polymerase chain reaction used to examine the T-cell antigen receptor gamma gene rearrangement showed polyclonal T-cell proliferation.
  • This is the second case of hepatocellular carcinoma combined with indolent T-lymphoblastic proliferation identified by an unusual tumor infiltrating lymphocytes.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. Lymphocytes, Tumor-Infiltrating / pathology. Precursor Cells, T-Lymphoid / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2007 Jun;132(7):2328-39 [17570208.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2424-6 [17107923.001]
  • [Cites] Chang Gung Med J. 2007 Mar-Apr;30(2):172-7 [17596007.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1529-33 [17708291.001]
  • [Cites] Immunol Rev. 2000 Apr;174:5-20 [10807503.001]
  • [Cites] Histopathology. 2000 Dec;37(6):523-9 [11122434.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):411-5 [11224614.001]
  • [Cites] Eur J Surg Oncol. 2004 Feb;30(1):53-7 [14736523.001]
  • [Cites] J Exp Med. 1990 Jul 1;172(1):7-12 [2141631.001]
  • [Cites] Vet Immunol Immunopathol. 1994 Oct;43(1-3):53-62 [7856064.001]
  • [Cites] J Exp Med. 1995 Sep 1;182(3):759-67 [7650483.001]
  • [Cites] Cell Immunol. 1996 May 1;169(2):159-65 [8620543.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):977-81 [10435569.001]
  • [Cites] Toxicol Pathol. 2005;33(1):52-62 [15805056.001]
  • [Cites] Hepatology. 2005 Apr;41(4):722-30 [15791620.001]
  • [Cites] J Reprod Immunol. 2005 Oct;67(1-2):35-50 [16111767.001]
  • [Cites] Cancer Immun. 2007;7:10 [17591743.001]
  • (PMID = 20119589.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD8; EC 2.7.7.31 / DNA Nucleotidylexotransferase
  • [Other-IDs] NLM/ PMC2811303
  • [Keywords] NOTNLM ; Carcinoma, Hepatocellular / Immunohistochemistry / Lymphocytes, Tumor-Infiltrating / indolent T-lymphoblastic proliferation
  •  go-up   go-down


88. Stevens SJ, Meers LE, Albrechts JC, Mebis-Verhees K, Bos GM, Engelen JJ, Janssen JW: A translocation in acute lymphoblastic leukemia that cytogenetically mimics the recurrent MLL-AFF1 translocation and fuses SEPT11 to MLL. Cancer Genet Cytogenet; 2010 Aug;201(1):48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A translocation in acute lymphoblastic leukemia that cytogenetically mimics the recurrent MLL-AFF1 translocation and fuses SEPT11 to MLL.
  • A 55-year-old man sought care for aggressive acute lymphoblastic leukemia (ALL), which developed 8 years after he had received chemotherapeutic treatment for nephrotic syndrome.
  • The sole cytogenetic abnormality observed in bone marrow-derived metaphases was a t(4;11)(q21;q23), which is a frequently occurring translocation in ALL.
  • However, subsequent reverse transcriptase-polymerase chain reaction for the expected mixed lineage leukemia [trithorax homolog, Drosophila] (MLL)-AFF1 fusion transcript was negative.
  • Thus, it is crucial to characterize cytogenetic aberrations in leukemia by molecular methods, even in cases where a known recurrent translocation is presumed.
  • Five septins have been identified thus far as MLL fusion partners in leukemia.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA-Binding Proteins / genetics. Gene Fusion. Myeloid-Lymphoid Leukemia Protein / genetics. Nuclear Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20633769.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / MLL protein, human; 0 / Nuclear Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 150826-18-9 / AFF1 protein, human; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 3.6.1.- / SEPT11 protein, human; EC 3.6.1.- / Septins
  •  go-up   go-down


89. Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D: Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104. J Leukoc Biol; 2005 Aug;78(2):359-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
  • The major histocompatibility complex nonrestricted cytotoxic leukemic T cell line T acute lymphoblastic leukemia (TALL)-104 is being pursued as a therapeutic agent for cancer.
  • Here, we examined the roles played by natural cytotoxicity receptors (NCR), killer cell immunoglobulin-like receptors, cytolytic granule components, and tumor necrosis factor (TNF) family members in tumor recognition and lysis by TALL-104 cells.
  • Although negative for the NCR natural killer (NK)p44, this cell line was found to express NKp46.
  • The data demonstrate the ability of TALL-104 cells to recognize a wide variety of tumors with NK cell receptors and kill them with a broad arsenal of cytolytic effector mechanisms, including cytolytic granules and TNF family ligands.
  • [MeSH-minor] Adoptive Transfer. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Antigens, CD / immunology. Antigens, CD3 / immunology. Apoptosis Regulatory Proteins. Carcinogens / pharmacology. Cell Degranulation / immunology. Fas Ligand Protein. Histocompatibility Antigens Class I / immunology. Humans. Immediate-Early Proteins / immunology. Ionomycin / pharmacology. Ionophores / pharmacology. Jurkat Cells. Membrane Glycoproteins / immunology. Monomeric GTP-Binding Proteins / immunology. NK Cell Lectin-Like Receptor Subfamily C. NK Cell Lectin-Like Receptor Subfamily K. Natural Cytotoxicity Triggering Receptor 1. Neoplasms / immunology. Neoplasms / therapy. Receptors, Immunologic / immunology. Receptors, KIR. Receptors, KIR3DL2. Receptors, Natural Killer Cell. TNF-Related Apoptosis-Inducing Ligand. Tetradecanoylphorbol Acetate / pharmacology. Tumor Necrosis Factor-alpha / immunology. Tumor Necrosis Factors / immunology. U937 Cells

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937142.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R01 CA20833; United States / NCI NIH HHS / CA / CA83859
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD3; 0 / Apoptosis Regulatory Proteins; 0 / CD244 protein, human; 0 / Carcinogens; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Histocompatibility Antigens Class I; 0 / Immediate-Early Proteins; 0 / Ionophores; 0 / KIR3DL2 protein, human; 0 / KLRC1 protein, human; 0 / KLRK1 protein, human; 0 / Membrane Glycoproteins; 0 / NCR1 protein, human; 0 / NK Cell Lectin-Like Receptor Subfamily C; 0 / NK Cell Lectin-Like Receptor Subfamily K; 0 / Natural Cytotoxicity Triggering Receptor 1; 0 / Receptors, Immunologic; 0 / Receptors, KIR; 0 / Receptors, KIR3DL2; 0 / Receptors, Natural Killer Cell; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Necrosis Factors; 56092-81-0 / Ionomycin; EC 3.6.5.2 / GEM protein, human; EC 3.6.5.2 / Monomeric GTP-Binding Proteins; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


90. Chowdhury S, Bandyopadhyay S, Mandal C, Chandra S, Mandal C: Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study. BMC Cancer; 2008;8:40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow-cytometric monitoring of disease-associated expression of 9-O-acetylated sialoglycoproteins in combination with known CD antigens, as an index for MRD in children with acute lymphoblastic leukaemia: a two-year longitudinal follow-up study.
  • BACKGROUND: Over expression of 9-O-acetylated sialoglycoproteins (Neu5,9Ac2-GPs, abbreviated as OAcSGP) has been demonstrated as a disease-associated antigen on the lymphoblasts of childhood acute lymphoblastic leukaemia (ALL).
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Sialoglycoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1570-83 [16026693.001]
  • [Cites] Curr Opin Pharmacol. 2005 Aug;5(4):431-7 [15955740.001]
  • [Cites] Glycobiology. 2006 Jan;16(1):1R-27R [16014749.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Leuk Lymphoma. 2006 Apr;47(4):769-70 [16886283.001]
  • [Cites] Indian J Biochem Biophys. 2006 Feb;43(1):7-14 [16955745.001]
  • [Cites] Glycobiology. 2000 Jun;10(6):539-49 [10814695.001]
  • [Cites] Br J Haematol. 2000 Sep;110(4):801-12 [11054061.001]
  • [Cites] Lancet Oncol. 2001 Oct;2(10):597-607 [11902549.001]
  • [Cites] Best Pract Res Clin Haematol. 2002 Mar;15(1):1-19 [11987913.001]
  • [Cites] Glycoconj J. 2001 Jul;18(7):529-37 [12151714.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2399-402 [12239148.001]
  • [Cites] Br J Haematol. 2003 Jun;121(6):823-38 [12786792.001]
  • [Cites] J Infect Dis. 2004 Apr 1;189(7):1257-64 [15031795.001]
  • [Cites] Clin Biochem. 2004 May;37(5):395-403 [15087256.001]
  • [Cites] Int J Cancer. 2004 Aug 20;111(2):270-7 [15197782.001]
  • [Cites] Glycobiology. 2004 Oct;14(10):859-70 [15190007.001]
  • [Cites] Science. 1984 Aug 24;225(4664):844-6 [6206564.001]
  • [Cites] Blood. 1988 Jul;72(1):299-307 [3291983.001]
  • [Cites] Biochem J. 1988 Aug 15;254(1):195-202 [3140796.001]
  • [Cites] Biochem J. 1989 Jan 1;257(1):65-71 [2920028.001]
  • [Cites] Experientia. 1990 May 15;46(5):433-41 [2189746.001]
  • [Cites] Carbohydr Res. 1995 Mar 1;268(1):115-25 [7736461.001]
  • [Cites] Immunol Lett. 1997 Dec;59(3):151-7 [9419022.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] Leukemia. 1999 Jan;13(1):119-25 [10049046.001]
  • [Cites] Leukemia. 1999 Feb;13(2):309-12 [10025909.001]
  • [Cites] Leukemia. 1999 Mar;13(3):419-27 [10086733.001]
  • [Cites] Ann Oncol. 1999 Feb;10(2):167-76 [10093685.001]
  • [Cites] Leuk Res. 1999 May;23(5):433-9 [10374857.001]
  • [Cites] Leuk Res. 1999 Sep;23(9):803-9 [10475619.001]
  • [Cites] J Infect Dis. 2004 Dec 1;190(11):2010-9 [15529267.001]
  • [Cites] Br J Haematol. 2005 Jan;128(1):35-41 [15606547.001]
  • [Cites] Int Immunol. 2005 Feb;17(2):177-91 [15629900.001]
  • [Cites] J Immunol Methods. 2005 Feb;297(1-2):13-26 [15777927.001]
  • [Cites] J Cell Biochem. 2005 May 1;95(1):206-16 [15770663.001]
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):623-34 [15704219.001]
  • (PMID = 18241334.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Sialoglycoproteins
  • [Other-IDs] NLM/ PMC2268943
  •  go-up   go-down


91. Castagnola E, Caviglia I, Pistorio A, Fioredda F, Micalizzi C, Viscoli C, Haupt R: Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution. Eur J Cancer; 2005 Jul;41(10):1439-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution.
  • The incidence rate (IR) of bloodstream infections (BI) and invasive mycoses (IM) during chemotherapy for paediatric acute lymphoblastic (ALL) or non-lymphoblastic leukaemias (AnLL) was evaluated for 153 BI and 22 IM diagnosed during 143,668 patient-days at risk from January 1988 to December 2000.
  • In conclusion, there is a correlation between intensity of chemotherapy and rate of infections in paediatric acute leukaemias.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Bacteremia / chemically induced. Leukemia, Myeloid, Acute / drug therapy. Mycoses / chemically induced. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2005 Jul;41(10):1370-1 [15913985.001]
  • (PMID = 15963894.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


92. Bakhshi S, Sethuraman G, Singh MK, Arya LS: Atypical pyoderma gangrenosum as a manifestation of childhood acute lymphoblastic leukemia. Pediatr Dermatol; 2005 Nov-Dec;22(6):543-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical pyoderma gangrenosum as a manifestation of childhood acute lymphoblastic leukemia.
  • We describe atypical pyoderma gangrenosum in association with acute lymphoblastic leukemia in a 2-year-old child, an occurrence not reported before.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyoderma Gangrenosum / drug therapy. Pyoderma Gangrenosum / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Asparaginase / therapeutic use. Biopsy, Needle. Child, Preschool. Daunorubicin / therapeutic use. Diagnosis, Differential. Follow-Up Studies. Humans. Immunohistochemistry. Male. Prednisone / therapeutic use. Risk Assessment. Severity of Illness Index. Treatment Outcome. Vincristine / therapeutic use


93. Ahmed D, Ahmed TA, Ahmed S, Tipu HN, Wiqar MA: CD5-positive acute lymphoblastic leukemia. J Coll Physicians Surg Pak; 2008 May;18(5):310-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD5-positive acute lymphoblastic leukemia.
  • CD5-positive B-ALL is a rare variant of Acute Lymphoblastic Leukemia (ALL).
  • This fourth case report describes a young lady who was diagnosed as ALL (L-2) on bone marrow examination and was found to be CD5 positive B-cell acute lymphoblastic leukemia on immunophenotyping.
  • [MeSH-major] Antigens, CD5 / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adult. Biopsy, Needle. Bone Marrow Cells / immunology. Bone Marrow Cells / pathology. Diagnosis, Differential. Female. Flow Cytometry. Humans

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18541090.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


94. Agarwal MR, Wagner P, Bedros AA: Unilateral optic nerve edema as the initial sign of recurrence of acute lymphoblastic leukemia. J Pediatr; 2006 May;148(5):703
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral optic nerve edema as the initial sign of recurrence of acute lymphoblastic leukemia.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / complications. Papilledema / etiology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737892.001).
  • [ISSN] 0022-3476
  • [Journal-full-title] The Journal of pediatrics
  • [ISO-abbreviation] J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Fakhoury M, Andreu-Gallien J, Mahr A, Medard Y, Azougagh S, Vilmer E, Jacqz-Aigrain E: Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia? J Clin Pharm Ther; 2007 Dec;32(6):633-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
  • METHODS: We determined the genotypic status and TMPT activity, at diagnosis and after 6 months of maintenance therapy, of 118 children with acute lymphoblastic leukaemia (ALL).
  • RESULTS AND DISCUSSION: Eighty-nine per cent of the children had a homozygous wild-type genotype (group 1), 11% had one or two mutant allele(s) (group 2).
  • At both time points, TPMT activity (U/mL peripheral red blood cell) was significantly higher in group 1 than in group 2 (P < 0.001) but inter-group levels overlapped considerably.
  • CONCLUSION: Genotyping at diagnosis identifies patients with a homozygous mutant TPMT and may prevent severe and life-threatening toxicity.
  • [MeSH-major] 6-Mercaptopurine / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Methyltransferases / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021342.001).
  • [ISSN] 0269-4727
  • [Journal-full-title] Journal of clinical pharmacy and therapeutics
  • [ISO-abbreviation] J Clin Pharm Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; EC 2.1.1.- / Methyltransferases; EC 2.1.1.67 / thiopurine methyltransferase
  •  go-up   go-down


96. Fitzmaurice GM, Lipsitz SR, Ibrahim JG, Gelber R, Lipshultz S: Estimation in regression models for longitudinal binary data with outcome-dependent follow-up. Biostatistics; 2006 Jul;7(3):469-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In many observational studies, individuals are measured repeatedly over time, although not necessarily at a set of pre-specified occasions.
  • Finally, we illustrate the main results using data from a longitudinal observational study that explored the cardiotoxic effects of doxorubicin chemotherapy for the treatment of acute lymphoblastic leukemia in children.
  • [MeSH-minor] Adolescent. Antibiotics, Antineoplastic / adverse effects. Bias (Epidemiology). Child. Child, Preschool. Computer Simulation. Doxorubicin / adverse effects. Echocardiography. Female. Follow-Up Studies. Heart Diseases / chemically induced. Heart Diseases / ultrasonography. Heart Ventricles / drug effects. Heart Ventricles / ultrasonography. Humans. Likelihood Functions. Male. Models, Statistical. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428260.001).
  • [ISSN] 1465-4644
  • [Journal-full-title] Biostatistics (Oxford, England)
  • [ISO-abbreviation] Biostatistics
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI 60373; United States / NCI NIH HHS / CA / CA 68484; United States / NCI NIH HHS / CA / CA 70101; United States / NCI NIH HHS / CA / CA 74015; United States / NCI NIH HHS / CA / CA 79063; United States / NIGMS NIH HHS / GM / GM 29745; United States / NIGMS NIH HHS / GM / GM 70335; United States / NHLBI NIH HHS / HL / HL 53392; United States / NHLBI NIH HHS / HL / HL 69800; United States / NHLBI NIH HHS / HL / HL 72705; United States / NHLBI NIH HHS / HL / HL 78522; United States / NHLBI NIH HHS / HR / HR 96041
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


97. Chen J, Jette C, Kanki JP, Aster JC, Look AT, Griffin JD: NOTCH1-induced T-cell leukemia in transgenic zebrafish. Leukemia; 2007 Mar;21(3):462-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NOTCH1-induced T-cell leukemia in transgenic zebrafish.
  • Activating mutations in the NOTCH1 gene have been found in about 60% of patients with T-cell acute lymphoblastic leukemia (T-ALL).
  • In order to study the molecular mechanisms by which altered Notch signaling induces leukemia, a zebrafish model of human NOTCH1-induced T-cell leukemia was generated.
  • Seven of sixteen mosaic fish developed a T-cell lymphoproliferative disease at about 5 months.
  • These neoplastic cells extensively invaded tissues throughout the fish and caused an aggressive and lethal leukemia when transplanted into irradiated recipient fish.
  • However, stable transgenic fish exhibited a longer latency for leukemia onset.
  • When the stable transgenic line was crossed with another line overexpressing the zebrafish bcl2 gene, the leukemia onset was dramatically accelerated, indicating synergy between the Notch pathway and the bcl2-mediated antiapoptotic pathway.
  • Reverse transcription-polymerase chain reaction analysis showed that Notch target genes such as her6 and her9 were highly expressed in NOTCH1-induced leukemias.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Leukemia-Lymphoma, Adult T-Cell / etiology. Proto-Oncogene Proteins c-bcl-2 / physiology. Receptor, Notch1 / physiology
  • [MeSH-minor] Animals. Animals, Genetically Modified. Apoptosis. Basic Helix-Loop-Helix Transcription Factors / physiology. Female. Gamma Rays. Gene Expression Profiling. Gene Expression Regulation, Leukemic. Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor. Genes, bcl-2. Humans. Male. Mosaicism. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Neoplasm Proteins / physiology. Neoplasm Transplantation. Oncogenes. Radiation Chimera. Radiation Tolerance. Recombinant Fusion Proteins / physiology. Signal Transduction. Time Factors. Zebrafish. Zebrafish Proteins / physiology

  • COS Scholar Universe. author profiles.
  • SciCrunch. ZFIN: Data: Gene Expression .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252014.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-36167; United States / NCI NIH HHS / CA / CA-68484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Her6 protein, zebrafish; 0 / NOTCH1 protein, human; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptor, Notch1; 0 / Recombinant Fusion Proteins; 0 / Zebrafish Proteins; 0 / her9 protein, zebrafish
  •  go-up   go-down


98. Aytac S, Yalcin SS, Cetin M, Yetgin S, Gumruk F, Tuncer M, Yurdakok K, Gurgey A: Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol; 2010 Aug;27(5):333-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measles, mumps, and rubella antibody status and response to immunization in children after therapy for acute lymphoblastic leukemia.
  • Seventy-seven patients with acute lymphoblastic leukemia (ALL) who were in complete remission and whose therapies had been stopped for at least 6 months before enrollment in this study were retrospectively analyzed regarding their antibody status for measles, mumps, and rubella, with the aim to demonstrate the seropositivity rate after treatment in the authors' group.
  • [MeSH-major] Antibodies, Viral / blood. Antibody Formation / drug effects. Measles-Mumps-Rubella Vaccine / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Measles.
  • Genetic Alliance. consumer health - Mumps.
  • Genetic Alliance. consumer health - Rubella.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20469978.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Measles-Mumps-Rubella Vaccine; 0 / rubella antibodies
  •  go-up   go-down


99. Valera ET, Brassesco MS, Germeshausen M, Silveira Vda S, Queiroz RG, Roxo P, Scrideli CA, de Menezes UP, Ferriani V, Tone LG: Acute lymphoblastic leukemia following severe congenital neutropenia or de novo ALL? Leuk Res; 2009 Sep;33(9):e139-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia following severe congenital neutropenia or de novo ALL?
  • Acute lymphoblastic leukemia (ALL) presenting with neutropenia alone is very rare.
  • Three months later she developed a pro-B ALL.
  • We identified a rare loss of 5'-MLL present at the diagnosis of SCN and ALL by FISH analysis using two different MLL (11q23) probes.
  • The early presence of 5'-MLL loss in bone marrow samples may favor the diagnosis of de novo ALL.
  • [MeSH-major] Neutropenia / congenital. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398129.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


100. Landau H, Lamanna N: Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. Curr Hematol Malig Rep; 2006 Sep;1(3):171-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults.
  • Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic and prognostic subgroups.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / classification. Burkitt Lymphoma / therapy. Central Nervous System / pathology. Child. Clinical Trials as Topic. Cranial Irradiation. Eye / pathology. Hematopoietic Stem Cell Transplantation. Humans. Immunophenotyping. Incidence. Leukemic Infiltration / drug therapy. Leukemic Infiltration / prevention & control. Leukemic Infiltration / radiotherapy. Lymphocyte Subsets / pathology. Male. Neoplasm, Residual. Prognosis. Remission Induction. Testis / pathology. Translocation, Genetic

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Hematol Rep. 2004 Jan;3(1):40-6 [14695849.001]
  • [Cites] Leukemia. 1998 Apr;12(4):463-73 [9557602.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] J Clin Oncol. 1983 Aug;1(8):462-70 [6583321.001]
  • [Cites] Lancet. 1996 Jun 29;347(9018):1783-8 [8667921.001]
  • [Cites] Leukemia. 1992;6 Suppl 2:178-81 [1578927.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2276-85 [15564544.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2480-5 [8823326.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3135-42 [8605327.001]
  • [Cites] Ann Intern Med. 1995 Sep 15;123(6):428-31 [7639442.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Blood. 1995 Apr 15;85(8):2025-37 [7718875.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1508-16 [10735899.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3707-21 [11054444.001]
  • [Cites] Blood. 1980 Feb;55(2):199-204 [6928104.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1094-104 [11844835.001]
  • [Cites] Blood. 1995 Feb 1;85(3):664-74 [7833470.001]
  • [Cites] J Clin Oncol. 1988 Jun;6(6):1014-30 [3163722.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2580-7 [7989932.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • [Cites] Blood. 1988 Nov;72(5):1784-9 [3052630.001]
  • [Cites] Leukemia. 2004 Dec;18(12):2032-5 [15483674.001]
  • [Cites] Blood. 1984 Jul;64(1):38-47 [6375764.001]
  • [Cites] Blood. 2002 Feb 1;99(3):863-71 [11806988.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):476-82 [9053468.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2461-70 [10561310.001]
  • [Cites] Blood. 2002 Sep 15;100(6):1965-71 [12200353.001]
  • [Cites] Curr Oncol Rep. 2005 Sep;7(5):323-32 [16091192.001]
  • [Cites] Blood. 1984 Jul;64(1):267-74 [6375760.001]
  • [Cites] Semin Oncol. 1987 Jun;14(2 Suppl 1):64-6 [3296208.001]
  • [Cites] Jpn J Clin Oncol. 1993 Apr;23(2):85-97 [7685836.001]
  • [Cites] Blood. 1996 Jun 15;87(12):5251-6 [8652840.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Leukemia. 2001 Dec;15(12):1811-22 [11753600.001]
  • [Cites] Blood. 1988 Jan;71(1):123-31 [3422030.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4014-22 [11600602.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1603-12 [8068949.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):460-6 [16344315.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2357-66 [12239143.001]
  • [Cites] N Engl J Med. 2004 Nov 25;351(22):2265-75 [15564543.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2464-71 [12011123.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):774-80 [12610173.001]
  • [Cites] Leukemia. 1991 May;5(5):425-31 [2033963.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4695-700 [12586618.001]
  • [Cites] Leukemia. 2005 May;19(5):734-40 [15789069.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1259-66 [12094249.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1509-16 [16034462.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):184-8 [12525508.001]
  • (PMID = 20425348.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down






Advertisement